WO2018110777A1 - Method for producing composite of high purity trisodium chlorin e6 and polyvinylpyrrolidone, and method for producing chlorin e6 - Google Patents
Method for producing composite of high purity trisodium chlorin e6 and polyvinylpyrrolidone, and method for producing chlorin e6 Download PDFInfo
- Publication number
- WO2018110777A1 WO2018110777A1 PCT/KR2017/005282 KR2017005282W WO2018110777A1 WO 2018110777 A1 WO2018110777 A1 WO 2018110777A1 KR 2017005282 W KR2017005282 W KR 2017005282W WO 2018110777 A1 WO2018110777 A1 WO 2018110777A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chlorin
- trisodium
- pvp
- polyvinylpyrrolidone
- chlorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Definitions
- the present invention relates to a method for producing a complex of high purity trisodium chlorin e6 (trisodium chlorin e6) and polyvinylpyrrolidone (PVP) and a method for producing chlorin e6.
- Conventional patents for producing chlorine e6 include complex chlorophyll extraction, acid treatment, neutralization, hydrolysis, extraction of pheophovida, dissolution with acetone, strong base addition, neutralization, and reprecipitation in spirulina or chlorella.
- a method for preparing chlorine six (hereinafter referred to as 'chlorine e6') through a long time extraction, separation or purification process is disclosed. In this method, chlorophyll a and pheophytin a are not completely purified, and then the reaction proceeds in the form of extracts and extracts, so the purity of the final material chlorine e6 is lowered.
- chlorine e6 prepared by conventional methods is not suitable for use in foods or pharmaceuticals, and also has a limitation in commercial use due to long reaction time and complicated reaction process.
- conventionally known methods for producing chlorine e6 from spirulina use harmful organic solvents, which are prohibited from use in the food or pharmaceutical fields, have a long reaction time and complexity, and do not have sterilization processes, and thus are not suitable for application to food or pharmaceutical production processes. There is a limit.
- a method of preparing chlorine e6 is provided.
- a method for preparing a composite of high purity trisodium chlorin e6 (PVSO) and polyvinylpyrrolidone (PVP) having a short production time and high reproducibility there is provided a method for preparing a composite of high purity trisodium chlorin e6 (PVSO) and polyvinylpyrrolidone (PVP) having a short production time and high reproducibility.
- PVSO trisodium chlorin e6
- PVP polyvinylpyrrolidone
- a method for preparing a complex of high purity trisodium chlorin e6 (polysodium chlorin e6) and polyvinylpyrrolidone (PVP) suitable for use as a food and pharmaceutical raw material by being sanitized and sanitized is provided.
- the mixing step is the following structure
- Trisodium Chlorin e6 (trisodium Chlorin e6) represented by the molecular formula C 34 ⁇ 33 ⁇ 6 N 4 Na 3 and the step of generating a complex of the polyvinylpyrrolidone (PVP), trisodium Chlorin e6 (trisodium Chlorin e6) And a method for preparing a composite of polyvinylpyrrolidone (PVP) may be provided.
- Extracting a chlorophyll extract by adding a chlorophyll-containing green plant or microalgae to methanol, ethanol, acetone or their respective aqueous solutions;
- purification of chlorophyll and pheophytin is included as an essential process.
- the effect of obtaining a high purity chlorophyll from the chlorophyll extract by using the difference in the solubility of hexane and water in the chlorophyll, dynamic compound wavelength ultrasonic process, porous alumina ceramic filter.
- water is added directly to the solution converted to pheophytin by adding acid to chlorophyll, neutralizing the reaction solution, and water
- an ultrasonic process to one reaction solution, the effect of improving the precipitation rate and precipitation rate of pheophytin and the effect of obtaining high purity pheophytin are simultaneously obtained.
- the process for preparing peotitin from chlorine e6 is carried out in the presence of a base, heating conditions, and sterile filtration process, thereby shortening the reaction time, improving the hygienic process and production yield. Get the effect.
- the process of converting the high purity chlorine e6 and PVP into a complex of water-soluble trisodium chlorine e6 and PVP by carrying out at a specific temperature, stirring, acid, and base presence conditions Get the effect of improving
- a trisodium chlorine e6 solution converted to water-soluble is subjected to a process of converting to a complex of trisodium chlorine e6 and PVP in the presence of an acid, a base, and at specific pH conditions and performing specific lyophilization Conditions are used to achieve the effect of drying into complexes usable for food and medicine.
- the converted trisodium chlorine e6 is sterilized and filtered and then lyophilized to be converted into a powder form of a complex of high purity trisodium chlorin e6 and PVP to food and pharmaceuticals.
- the effect of improving the production yield is obtained by producing a composite usable in
- FIG. 1 shows the HPLC analysis of the chlorophyll extract prepared according to an embodiment of the present invention.
- FIG. 2 shows the HPLC analysis of the high purity chlorophyll extract prepared according to an embodiment of the present invention.
- Figure 3 shows the results of HPLC analysis for pheophytin prepared according to an embodiment of the present invention.
- FIG. 4 shows the results of nuclear magnetic resonance (NMR) analysis of high purity Chlorin e6 (Chlorin e6) prepared according to an embodiment of the present invention.
- FIG. 5 shows the results of HPLC analysis of Chlorin e6 (Chlorin e6) prepared according to an embodiment of the present invention.
- FIG. 6 shows the results of Liquid Chromatography Mass Spectrometry LC / MS analysis of Chlorin e6 prepared according to one embodiment of the present invention.
- FIG. 7 shows the results of HPLC comparison analysis of a high purity trisodium chlorin e6 (sample) prepared in accordance with an embodiment of the present invention and a commercial product (standard-Frontiers).
- Figure 8 shows the measurement results of the ultraviolet visible absorbance measurement method of trisodium chlorin e6 (trisodium Chlorin e6) and the molecular weight of 10,000 or less PVP composite prepared according to an embodiment of the present invention.
- Figure 9 shows the formula for calculating the content of trisodium Chlorin e6 (trisodium Chlorin e6) according to an embodiment of the present invention.
- FIG. 10 shows the results of comparative absorbance analysis using UV / VIS Spectrophotometry in trisodium chlorin e6 and PVP composite according to an embodiment of the present invention.
- cancer and “tumor” generally mean or describe physiological conditions in a mammal characterized by uncontrolled cell growth. Benign and malignant cancers, and dormant tumors or micrometastases are included in this definition. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Other examples of such cancers include skin cancer, cleft lip cancer, melanoma (skin metastasis), breast cancer (skin metastasis), skin basal cell cancer, deformed skin cancer, skin squamous cell carcinoma, and squamous cell carcinoma of the lower lip. It is not limited to.
- cancers include breast cancer, squamous cell cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma and squamous carcinoma of the lung), systemic glioblastoma, glioblastoma, typical glioblastoma and mesenchymal glioblastoma, Cancer of the peritoneum, gastric cancer, gastric cancer (including gastrointestinal cancer), pancreatic cancer, ovarian cancer, cervical cancer, liver cancer, bladder cancer, colon cancer, colorectal cancer, endometrial cancer, uterine carcinoma, salivary gland carcinoma, kidney cancer, prostate cancer, vulvar cancer , Thyroid cancer, various types of head and neck cancer, B cell lymphoma (non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; medium / follicular NHL; medium grade) Diffuse NHL; High Grade Immunoblastic NHL; High Grade Lymphoblastic NHL; High Grade Small Non
- cancer and “tumor” refer to all neoplastic growth and proliferation (either malignant or benign), and all precancerous and cancerous cells and tissues.
- cancer cancer, “cancerous”, “cell proliferative disorder”, “proliferative disorder” and “tumor” are referred to herein and are not mutually exclusive.
- 'chlorine e six' may be represented by 'Chlorin e6' or 'chlorine e6'.
- the term 'composite' is used to mean a complex of trisodium Chlorin e6 and polyvinylpyrrolidone (hereinafter referred to as "PVP") (polyvinylpyrrolidone) having a molecular weight of 15,000 or less.
- PVP polyvinylpyrrolidone
- the complex of trisodium Chlorin e6 and trivinylpyrrolidone (PVP) prepared according to an embodiment of the present invention may be used as a pharmaceutical composition for treating cancer photodynamically.
- trisodium Chlorin e6 and PVP (polyvinylpyrrolidone) composite production method Chlorin e6, polyvinylpyrrolidone (PVP), NaOH, HCl and the result of the step of mixing the frozen result Drying to powder.
- Chlorin e6 has the structure
- the mixing step has the following structure
- PVP polyvinylpyrrolidone
- the step of sterilizing and filtering Chlorin e6 (S50) is performed before performing the mixing step (S100).
- the step of sterilization and filtration (S50), the first pH adjustment step of dissolving Chlorin e6 in water, adjusting the pH to less than 7 pH of the lysate; a second pH adjusting step of adjusting the pH of the lysate having a pH less than 7 to 7 or more; And sterilizing and filtering the lysate having a pH of 7 or more using a micro filter.
- the micro filter may be, for example, having a diameter of 0.22 ⁇ m, but this value is exemplary.
- the first pH adjusting step is adjusting the pH of the lysate to 2
- the second pH adjusting step is adjusting the pH of the lysate to 7.1.
- the mixing step (S100) includes adjusting the pH of the mixture as a result of performing the mixing step (S100) to 7 to 9.
- the mixing step (S100), the step of adjusting the pH of the mixture resulting from the mixing step (S100) to 7 to 9 and sterilizing and filtering the mixture using a micro filter It can be implemented to include.
- the mixing step S100 may be performed such that the weight percentage of NaCl in the mixture is 5% or less.
- the mixing step S110 may include adjusting the pH of the mixture resulting from the mixing step S110 to 7 to 9 and sterilizing and filtering the mixture using a micro filter.
- the micro filter may be, for example, having a diameter of 0.22 ⁇ m but this value is exemplary.
- the mixing step S100 may be performed such that the weight percentage of NaCl in the mixture is 5% or less.
- 'composite' refers to a complex of trisodium Chlorin e6 and polyvinylpyrrolidone (PVP).
- trisodium chlorin e6 and polyvinylpyrrolidone (PVP) may be composed of 1: 9, 5: 5, 4: 6, or 6: 4, 9: 1.
- the mixing step S100 is performed such that the pH of the mixture, which is a result of performing the mixing step, becomes 7-9.
- Chlorin e6 and a molecular weight of 15,000 or less polyvinylpyrrolidone (PVP) may be mixed first, and then a mixture of chlorin e6 and polyvinylpyrrolidone (PVP) may be implemented by mixing NaOH and HCl.
- the number of moles of NaOH and HCl is set so that the pH of the result of the mixing step is 7 to 9.
- the mixing step (S100) is
- Chlorin e6 and NaOH and HCl may be mixed first, and then a mixture of Chlorin e6 and NaOH and HCl and polyvinylpyrrolidone (PVP) may be implemented.
- PVP polyvinylpyrrolidone
- the number of moles of NaOH and HCl is set so that the pH of the result of the mixing step is 7 to 9.
- the mixing step (S100) is performed by reacting step (S100)
- Chlorin e6 and NaOH and HCl and PVP polyvinylpyrrolidone
- the pH of the mixture can be implemented by a method of 7 to 9.
- Chlorin e6 prepared according to the present method can be used to prepare the complexes described above.
- Method for preparing chlorin e6 the green plant or microalgae containing chlorophyll in a methanol, ethanol, acetone or each of these aqueous solution to extract the chlorophyll extract, chlorophyll extract hexane and Adding water and stirring, separating the hexane layer from the stirred solution to purify the chlorophyll, dissolving the purified chlorophyll in a solvent of any one of methanol, ethanol, acetone and a mixed solvent thereof, and then adding an acid. Acidifying, adding water to the result of the acidifying step to obtain a pheophytin precipitate, and dissolving the pheophytin precipitate in acetone and adding a base to produce chlorine e6. .
- the extracting may include adding green plants or microalgae to methanol, ethanol, acetone or their respective aqueous solutions, and applying ultrasonic waves to the aqueous solutions.
- the ultrasound may have a frequency of 10 to 50 kHz.
- the present embodiment may further include a step of separating and concentrating the result of performing the extracting step using a filter before performing the stirring step.
- the stirring may include adding hexane and water to the chlorophyll extract to generate a first mixture, and stirring the first mixture while applying ultrasonic waves to the mixture.
- the ultrasound may have a frequency of 10 to 50 kHz.
- Chlorophyll a and b extracted and purified according to the method for extracting and purifying chlorophyll a and b according to an embodiment of the present invention may be used to prepare the above-mentioned complex.
- a green plant or microalgae containing spirulina is obtained by extracting chlorophyll using a dynamic compound wavelength ultrasonic extraction technique.
- green plants or microalgae are stirred with a solvent having a relatively high polarity, such as water, methanol, ethanol, acetone, and an aqueous solution thereof, and an ultrasonic extraction method is applied to the stirred solution.
- a porous alumina ceramic filter (5-20 ⁇ m) is applied to the resultant obtained by applying the ultrasonic extraction method, and separated and concentrated to obtain a chlorophyll extract. Then, hexane with high solubility in chlorophyll and relatively low polarity is added to the chlorophyll extract.
- the chlorophyll extract to which hexane is added is subjected to ultrasonic extraction and stirring to move the chlorophyll to the hexane layer as much as possible. Thereafter, when water is added to the resultant to which the ultrasonic extraction and stirring process is applied and stirred, impurities other than chlorophyll, which may be included in the hexane layer, are transferred to the water layer, thereby obtaining high purity chlorophyll from the hexane layer.
- hexane has a nonpolar characteristic such as chlorophyll, so that it has high solubility in chlorophyll, and hexane has a property of being separated without mixing with methanol, ethanol, acetone or their respective aqueous solutions. Therefore, by purifying chlorophyll extract using ultrasonic wave, hexane and water, chlorophyll is more easily dissolved and distributed in the hexane layer, and impurities other than chlorophyll are easily separated and distributed into water, methanol, ethanol or acetone layers. It is possible to obtain high purity chlorophyll.
- the ultrasonic wave used to extract chlorophyll in spirulina can be adjusted to 10-50 kHz, 100-500 W, and the time taken to reach 100% extraction rate is up to 2 hours, which is more effective than the existing 6 to 12 hours. It is economical.
- the water content in the extractant can be adjusted to less than 30% by volume.
- the reason is that the use of ultrasonic extraction equipment enables the extraction of chlorophyll in a short time, thereby preventing the decomposition and denaturation of chlorophyll.
- the purified solvent hexane used in conjunction with the ultrasonic wave can be reduced to within 3 times the volume of the concentrated chlorophyll extract.
- the use of ultrasound allows the chlorophyll to move easily into the hexane layer with a relatively small amount of hexane, thereby economically increasing the yield of chlorophyll.
- the stirring time is less than 1 hour, and when ultrasonic waves are not used, the stirring time is shorter than 3 hours.
- the chlorophyll is further extracted by using ultrasonic waves and water can be further maximized the purification effect of chlorophyll. That is, it is possible to easily transfer impurities to the aqueous layer by sonication and water to obtain high purity chlorophyll from the hexane layer.
- a filtration process using a porous alumina ceramic filter (5-20 ⁇ m) may be performed.
- the frequency of the ultrasonic wave is 10 to 50 kHz, the power is adjusted to 100 to 500 W, and a short time treatment such as within 5 to 10 minutes is preferable.
- the use of ultrasonic waves in this process is economical since emulsion formation can be prevented.
- the conventional three-day process period can be shortened within 12 hours, and the purified chlorophyll a and b have a purity of 90% or more.
- This method is a method for obtaining pheophytin according to an embodiment of the present invention.
- chlorophyll-a represented by the following formula (1) is treated with an acid to obtain a phephytin represented by the following formula (2) from which magnesium is removed.
- the acid is added and sonicated (10-50 kHz, adjustable to 100-500 W) and stirred at room temperature.
- the magnesium atom contained in the chlorophyll molecule is released and converted into phefitin within 30 minutes to 1 hour.
- the acid added for magnesium desorption is within 3 equivalents per molecule of chlorophyll, and the pH of the reaction solution is adjusted in the range of 1 to 3.
- the amount of acid used is economical because it is used in a small amount together with the sonication, and there is a characteristic that can prevent the formation of the pheopovid by-products due to overreaction.
- the kind of acid added for the desorption of magnesium may be selected from conventional inorganic acids such as hydrochloric acid, sulfuric acid, or phosphoric acid, or organic acids such as acetic acid and the like.
- the purity of the intermediate chlorine e6 can be increased by economically separating and purifying the pheophytin produced by adding acid in addition to sonication economically.
- the pheophytin produced by sonication and acid treatment as described above is filtered by a porous alumina ceramic filter (5-20 ⁇ m).
- the filtered pheophytin precipitate is then cooled while maintaining at a low temperature of -20 ° C to -40 ° C and a low pressure of 20mbar and water is removed using a cold trap (-70 ° C to -80 ° C).
- a cold trap -70 ° C to -80 ° C.
- a vacuum state is formed in which moisture can be sublimed and removed.
- sublimation drying in the frozen state does not cure or shrink the surface of the pheophytin particles.
- Many new drugs can be damaged by overdrying, so the final amount of water is maintained at the best level when the final moisture is dried between 1.5% and 2.0%.
- the ultrasonic wave (adjustable to 10 to 50 kHz, 100 to 500 W) is applied to the chlorophyll-dissolved solution and washing with ethanol and water is performed,
- the purification effect of tin can be further maximized. That is, by the sonication and the addition of ethanol and water, impurities can be easily transferred to the aqueous solution layer to obtain a high purity pheophytin from the hexane layer.
- the ultrasonic waves to be treated can be adjusted to 10 to 50 kHz, 100 to 500 W, and a short time is processed within 5 to 10 minutes.
- the pheophytin precipitate obtained through the above acid treatment method and obtained through the porous alumina ceramic filter has a purity of 95% or more and is obtained in a yield of 95% or more based on the weight of chlorophyll used.
- This method is a method for producing chlorine e6 according to an embodiment of the present invention.
- chlorine e6 represented by the following Chemical Formula 3 is obtained by adding a base to pheophytin and heating the reaction.
- the concentrated phephytin dry matter is dissolved in acetone.
- the remaining moisture of the dissolved acetone solution is removed using Na 2 SO 4 , and added to the reflux reactor together with ethanol.
- the pH is adjusted to 13 or higher using sodium hydroxide at 60 ° C. to 70 ° C. reflux.
- the base is commonly used, and may be an inorganic base such as a hydroxide of an alkali metal or an alkaline earth metal, or an organic base such as an ammonium salt. pH titration can be rapidly titrated in real time using a potentiometric automatic titrator.
- Chlorin e6 obtained from the reactants using a porous alumina ceramic filter (5-20 ⁇ m), and the obtained chlorine e6 is dried by vacuum and drying process.
- Chlorin e6 obtained by the above method is at least 90% and is obtained in a yield of at least 90% based on the weight of the pheophytin used.
- This method is a chlorine e6 purification method according to an embodiment of the present invention.
- this method is a process of obtaining the high purity chlorine e6 by performing acid treatment and alkali treatment on the dried chlorine e6.
- the pH is adjusted to 7-9 using a potentiometric autotitrator, and microparticles which are not dissolved in water are removed by sterile filtration using a 0.22 ⁇ m microfilter.
- the pH of the lysate was adjusted to 2 using a potentiometric autotitrator and chlorine e6 was obtained by sterile filtration using a 0.22 ⁇ m microfilter.
- chlorine e6 it is added to 1% by weight in ethanol and stirred for at least 1 hour, followed by vacuum drying to obtain high purity chlorine e6. Chlorine e6 obtained by the above method is 95% or more.
- the dried high purity chlorine e6 is then dissolved in acetone or water, the pH is slowly adjusted to 8.5, sterilized using a 0.22 ⁇ m microfilter and dried by lyophilization process.
- high purity trisodium chlorine e6 is obtained.
- the method is a method for producing trisodium chlorine e6 and PVP complex according to an embodiment of the present invention.
- high purity chlorine e6 or high purity trisodium chlorine e6 is stirred and mixed with PVP in an aqueous solution at room temperature in one-to-one or one-to-one or teenage days.
- the pH of the mixture is adjusted to 7 to 9 using a potentiometric automatic titrator to maintain a minimum amount of NaCl to prepare trisodium chlorine e6 and PVP complex.
- stirring is carried out within 1 hour.
- the complex is sterile filtered with a 0.22 ⁇ m microfilter.
- the sterile filtered complex is then cooled for freeze-drying while maintaining a low temperature of -20 ° C to -40 ° C and a low pressure of 20 mbar and water is removed using a cold trap (-70 ° C to -80 ° C).
- a cold trap -70 ° C to -80 ° C.
- the water becomes a vacuum state in which water can be sublimated and removed. Sublimation drying in the frozen state does not cure or shrink the surface of the composite.
- the final amount of moisture is kept dry between 1.5% and 2% as damage may be caused by excessive drying.
- trisodium chlorine e6 is separated, extracted, and purified from a chlorophyll-containing starting material economically using a short-term process without any limitation of specific raw materials.
- the new hygienic process through sterile filtration greatly improves the physiological activity, and by using ultrasonic waves to significantly improve the yield for a short time has the characteristics of synthesizing trisodium chlorine e6 complex in a process suitable for mass drug production.
- Extraction solvent 750 liters of ethanol was added to 75 kg of spirulina, sonicated (30 kHz, 300 W), stirred for 1 hour, and filtered using a porous alumina ceramic filter (5-20 ⁇ m) to obtain a chlorophyll extract.
- the chlorophyll extract obtained above was analyzed by HPLC (High Pressure Liquid Chromatography) under the following conditions.
- the solvent used was methanol, acetonitrile, dichloromethane, water and the like, and HPLC analysis was performed at 450 nm. HPLC analysis of the chlorophyll extract obtained above is shown in FIG. According to the HPLC analysis results shown in FIG.
- the chlorophyll extract obtained in Experiment 2 was concentrated to a maximum volume of 10%, and the same volume of hexane was added to the concentrated chlorophyll extract, followed by stirring with sonication (20 kHz, 300 W) for 30 minutes. An additional volume of water equal to hexane was added and stirring continued for 10 minutes with sonication. After stirring the reaction solution at -10 °C for 5 hours, the reaction solution was separated by layers to obtain an organic layer. Thereafter, the organic layer was distilled under reduced pressure to obtain high purity chlorophyll. HPLC analysis of the obtained chlorophyll extract is shown in FIG. According to the HPLC analysis results shown in FIG . 2 , it was confirmed that impurities between 0 and 3 minutes were almost removed. In addition, it was confirmed that the purification degree of chlorophyll is about 90%. The yield of this means that 90% or more of the extract was extracted relative to the amount of chlorophyll contained in the starting material.
- the pheophytin precipitate obtained by the above acid treatment method has a purity of 95% or more and is obtained in a yield of 95% or more based on the weight of chlorophyll used.
- the obtained chlorine e6 was analyzed by HPLC at 407 nm using acetonitrile and 0.1% trifluoroacetic acid solvent (Fig. 5).
- peaks corresponding to chlorine e6 were observed at retention time of 3 to 4 minutes, and impurities were hardly identified at other time points.
- the purity of chlorine e6 was confirmed to be about 95% or more.
- the results of liquid chromatography mass spectrometry confirmed that the corresponding peak of chlorine e6, it was confirmed that the impurities are almost removed (Fig. 6).
- the chlorine e6 solution is sterilized and filtered using a 0.22 ⁇ m microfilter to obtain chlorine e6.
- the obtained chlorine e6 was dissolved in 95% or more of acetone, then the pH was adjusted to 7.1, sterilized, filtered and vacuum dried to obtain high purity chlorine e6.
- the chlorine e6 solution is adjusted to pH 7-9 to form trisodium chlorine e6, then sterilized, filtered and lyophilized using a 0.22 ⁇ m micro filter to obtain high purity trisodium chlorine e6.
- HPLC analysis of the obtained high-purity trisodium chlorine e6 confirmed the corresponding peak of chlorine e6 at retention time of 4 minutes, and has a purity of at least 95% compared to commercially available chlorine e6 reagent (Frontiers). It was confirmed that the impurities were almost removed (Fig. 7).
- the complex is sterile filtered with a 0.22 ⁇ m microfilter.
- the sterile filtered complex is then cooled for freeze-drying while maintaining a low temperature of -20 ° C to -40 ° C and a low pressure of 20 mbar and water is removed using a cold trap (-70 ° C to -80 ° C).
- a cold trap -70 ° C to -80 ° C.
- the water becomes a vacuum state in which water can be sublimated and removed.
- Sublimation drying in the frozen state does not cure or shrink the surface of the composite.
- the amount of final moisture is maintained to be dried between 1.5%-2%.
- the composite according to an embodiment of the present invention is well dissolved in water, and the solution prepared for the content test is black green.
- 200 mg of the complex according to one embodiment of the present invention is diluted with 25 mL of water and left for 10 minutes. Take 0.2 mL of this solution into a 100 mL volumetric flask and add a diluent (95% ethanol) to dissolve completely. Absorption is shown at wavelengths of 402.4, 503.2, 531.7, 608.0, and 662.7 when the absorption spectrum is measured at 400-700 nm according to the ultraviolet visible absorbance measurement method (see FIG. 8).
- a solution of 200 mg of the complex according to one embodiment of the present invention diluted with 25 mL of water is left for 10 minutes. After leaving for 10 minutes, take 0.2 mL of the solution, place it in a 100 mL flask, add diluent (95% ethanol) to the mark, and dissolve to prepare a sample solution (standard solution: 95% ethanol).
- the sample solution and the standard solution were put into a 1 cm spectrophotometer cell and calculated by measuring the transmittance at 662 nm according to the UV-visible absorbance measurement method (refer to the formula of FIG. 9). Preparation of all test substances is carried out under shading. Accuracy is calculated as recovery at each concentration and average recovery should be within 100% of each concentration. Precision should be calculated as a coefficient of variation for the recovery of each concentration and should be less than 5%.
- the formula for calculating the recovery rate is as follows.
- the chlorine e6 in physiological saline was analyzed using UV / VIS Spectrophotometry. Through this analysis, the accuracy (complex 1), precision (complex 2) and stability (composite 3) were investigated.
- Chlorin e6 To prepare an injection preparation of 100 mg / mL (as Chlorin e6), add excipients to the complex and dissolve by ultrasonic shaking for about 30 minutes. Low concentration preparations are prepared by dilution with excipients from high concentration preparations (100 mg / mL) to the desired concentration of 1 mg / mL. Preparation of all test substances is carried out under shading. Chlorin e6 at 2.5, 5 and 10 mg / mL in excipients are assessed by intra-day and inter-day analysis. In-day analysis is performed at three concentrations by preparing three samples per concentration.
- the daily analysis is evaluated with a result of at least 3 days in the same manner as the daily analysis, and one sample is performed by another experimenter to confirm the reproducibility between the experimenters.
- Accuracy is calculated as recovery at each concentration and average recovery should be within 100% of each concentration.
- Precision is calculated as the coefficient of variation for the recovery of each concentration and should be less than 5%.
- the stability of the complex is taken three times in the middle layer after storage of 2.5, 10 mg / mL of the complex sample in excipients at each storage condition. Each sample is shaded and stored for about 7 days in refrigeration.
- the conformance criteria should be within 100% of the theoretical concentration. Referring to FIG. 10, reference may be made to an analysis result of chlorine e6 for accuracy, precision, and stability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법과 Chlorin e6의 제조 방법에 관한 것이다. The present invention relates to a method for producing a complex of high purity trisodium chlorin e6 (trisodium chlorin e6) and polyvinylpyrrolidone (PVP) and a method for producing chlorin e6.
종래 클로린 e6를 제조하는 특허문헌들에는, 스피루리나 또는 클로렐라에서 클로로필 추출, 산 처리, 중화, 가수분해, 페오포비드 a의 추출, 아세톤에 의한 용해, 강염기 첨가, 중화, 및 재침전 등의 복잡하고 오랜 시간 추출, 분리, 또는 정제 과정을 통해 클로린 이 식스(이하, ‘클로린 e6’라고 함)를 제조하는 방법이 개시되어 있다. 이러한 방법은 클로로필 a와 페오피틴 a가 완전 정제된 상태가 아닌 추출액과 추출물 형태로 그 다음 반응이 진행되므로, 최종물질인 클로린 e6의 순도는 낮아진다.Conventional patents for producing chlorine e6 include complex chlorophyll extraction, acid treatment, neutralization, hydrolysis, extraction of pheophovida, dissolution with acetone, strong base addition, neutralization, and reprecipitation in spirulina or chlorella. A method for preparing chlorine six (hereinafter referred to as 'chlorine e6') through a long time extraction, separation or purification process is disclosed. In this method, chlorophyll a and pheophytin a are not completely purified, and then the reaction proceeds in the form of extracts and extracts, so the purity of the final material chlorine e6 is lowered.
또한 종래 방법들에 의해 제조된 클로린 e6는 식품이나 의약품에 사용되기에는 부적합하고, 또한 긴 반응시간과 복잡한 반응과정으로 인하여 상업적으로 이용하기에는 한계가 있다. 특히 스피루리나로부터 클로린 e6를 제조하는 종래의 알려진 방법은 식품 또는 의약품 분야에서 사용이 금지된 유해 유기용매를 사용하고, 반응 시간도 길고 복잡할 뿐만 아니라 멸균공정이 없어서,식품 이나 의약품 생산공정에 적용하기에는 한계가 있다.In addition, chlorine e6 prepared by conventional methods is not suitable for use in foods or pharmaceuticals, and also has a limitation in commercial use due to long reaction time and complicated reaction process. In particular, conventionally known methods for producing chlorine e6 from spirulina use harmful organic solvents, which are prohibited from use in the food or pharmaceutical fields, have a long reaction time and complexity, and do not have sterilization processes, and thus are not suitable for application to food or pharmaceutical production processes. There is a limit.
본 발명의 일 실시예에 따르면 클로린 e6의 제조 방법이 제공된다.According to one embodiment of the present invention, a method of preparing chlorine e6 is provided.
본 발명의 일 실시예에 따르면, 짧은 제조 시간 및 높은 재현성을 가지는 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법이 제공된다. According to an embodiment of the present invention, there is provided a method for preparing a composite of high purity trisodium chlorin e6 (PVSO) and polyvinylpyrrolidone (PVP) having a short production time and high reproducibility.
본 발명의 일 실시예에 따르면, 위생적으로 멸균 처리되어 식품 및 의약품 원료로 사용하기 적합한 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법이 제공된다.According to one embodiment of the present invention, a method for preparing a complex of high purity trisodium chlorin e6 (polysodium chlorin e6) and polyvinylpyrrolidone (PVP) suitable for use as a food and pharmaceutical raw material by being sanitized and sanitized is provided.
본 발명의 일 실시예에 따르면 다음의 구조According to an embodiment of the present invention the following structure
를 가지고, 분자식(molecular formula) C34H36N4O6 로 표현되는 클로린 e6(Chlorin e6), PVP (polyvinylpyrrolidone), NaOH, 및 HCl을 혼합하는 단계; 및Mixing chlorine e6 (Chlorin e6), PVP (polyvinylpyrrolidone), NaOH, and HCl represented by a molecular formula C 34 H 36 N 4 O 6 ; And
상기 혼합하는 단계의 수행 결과물을 동결 건조시켜 분말로 만드는 단계;를 포함하며, And freeze-drying the resultant of the mixing step into powder.
상기 혼합하는 단계는 다음의 구조The mixing step is the following structure
를 가지며 분자식 C34Н33О6N4Na3로 표현되는 트리소듐 클로린 e6(trisodium Chlorin e6)와 상기 PVP(polyvinylpyrrolidone)의 복합체를 생성하는 단계인 것인, 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법이 제공될 수 있다.Trisodium Chlorin e6 (trisodium Chlorin e6) represented by the molecular formula C 34 Н 33 О 6 N 4 Na 3 and the step of generating a complex of the polyvinylpyrrolidone (PVP), trisodium Chlorin e6 (trisodium Chlorin e6) And a method for preparing a composite of polyvinylpyrrolidone (PVP) may be provided.
본 발명의 다른 실시예에 따르면, 클로린 e6(Chlorin e6)를 제조하는 방법에 있어서, According to another embodiment of the present invention, in the method for preparing chlorine e6 (Chlorin e6),
클로로필을 함유하는 녹색식물 또는 미세조류를 메탄올, 에탄올, 아세톤 또는 이들 각각의 수용액에 넣어 클로로필 추출물을 추출하는 단계;Extracting a chlorophyll extract by adding a chlorophyll-containing green plant or microalgae to methanol, ethanol, acetone or their respective aqueous solutions;
상기 클로로필 추출물에 헥산과 물을 넣고 교반 하는 단계;Adding hexane and water to the chlorophyll extract and stirring;
교반 된 용액에서 헥산 층을 분리하여 클로로필을 정제하는 단계;Purifying chlorophyll by separating the hexane layer from the stirred solution;
정제된 클로로필을 메탄올, 에탄올, 아세톤 및 이들의 혼합용매 중 어느 하나의 용매에 용해시킨 후, 산을 첨가하여 산성화하는 단계;Dissolving the purified chlorophyll in a solvent of any one of methanol, ethanol, acetone, and a mixed solvent thereof, and then acidifying by adding an acid;
상기 산성화하는 단계의 수행 결과물에 물을 첨가하여 페오피틴(pheophytin) 침전물을 획득하는 단계; 및Adding water to the resultant of the acidifying step to obtain a pheophytin precipitate; And
상기 페오피틴 침전물을 아세톤에 용해시키고 염기를 첨가하여 클로린 e6을 생성하는 단계;를 포함하는 것인, 클로린 e6(Chlorin e6)를 제조하는 방법이 제공될 수 있다. Dissolving the pheophytin precipitate in acetone and adding a base to produce chlorine e6; which may include providing a method for producing chlorine e6 (Chlorin e6).
본 발명의 하나 이상의 실시예들에 따르면, 스피루리나로부터 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP의 복합체를 제조하는 일련의 과정을 수행함에 있어, 클로로필 및 페오피틴의 정제과정을 필수 공정으로 포함하여 최종적으로 제조되는 i) 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)의 순도와 정제 공정기간 또는 ii) 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP 의 복합체의 순도와 정제 공정기간을 크게 개선하는 효과를 얻는다. According to one or more embodiments of the present invention, in the process of preparing a complex of trisodium chlorin e6 and PVP from spirulina, purification of chlorophyll and pheophytin is included as an essential process. I) purity and refining process period of i) high purity trisodium chlorin e6 or ii) complex of high purity trisodium chlorin e6 and PVP Get the effect.
또한, 본 발명의 하나 이상의 실시예들에 따르면, 클로로필에 대한 헥산과 물의 용해도 차이, 동적 복합파장 초음파 공정, 다공성 알루미나 세라믹필터를 이용하여 클로로필 추출물로부터 순도 높은 클로로필을 수득하는 효과를 얻는다.In addition, according to one or more embodiments of the present invention, the effect of obtaining a high purity chlorophyll from the chlorophyll extract by using the difference in the solubility of hexane and water in the chlorophyll, dynamic compound wavelength ultrasonic process, porous alumina ceramic filter.
또한, 본 발명의 하나 이상의 실시예들에 따르면, 고순도 페오피틴을 제조함에 있어서, 클로로필에 산을 가하여 페오피틴으로 전환한 용액에, 물을 직접 투입하여 반응용액을 중화시키고, 물을 투입한 반응 용액에 초음파공정을 적용함으로써 페오피틴의 침전속도 및 침전율을 향상시키는 효과와 순도 높은 페오피틴을 수득하는 효과를 동시에 얻는다.In addition, according to one or more embodiments of the present invention, in the preparation of high-purity pheophytin, water is added directly to the solution converted to pheophytin by adding acid to chlorophyll, neutralizing the reaction solution, and water By applying an ultrasonic process to one reaction solution, the effect of improving the precipitation rate and precipitation rate of pheophytin and the effect of obtaining high purity pheophytin are simultaneously obtained.
또한, 본 발명의 하나 이상의 실시예들에 따르면, 클로린 e6으로부터 페오티틴을 제조하는 과정을 염기 존재, 가열 조건, 및 멸균여과 공정에서 수행함으로써, 반응시간의 단축, 위생적 공정 및 제조 수율을 향상시키는 효과를 얻는다.In addition, according to one or more embodiments of the present invention, the process for preparing peotitin from chlorine e6 is carried out in the presence of a base, heating conditions, and sterile filtration process, thereby shortening the reaction time, improving the hygienic process and production yield. Get the effect.
또한, 본 발명의 하나 이상의 실시예들에 따르면, 고순도 클로린 e6와 PVP를 특정 온도, 교반, 산, 및 염기 존재 조건에서 수행하여 수용성 트리소듐 클로린 e6 와 PVP의 복합체로 전환하는 과정으로 제조 수율을 향상시키는 효과를 얻는다.In addition, according to one or more embodiments of the present invention, the process of converting the high purity chlorine e6 and PVP into a complex of water-soluble trisodium chlorine e6 and PVP by carrying out at a specific temperature, stirring, acid, and base presence conditions Get the effect of improving
또한, 본 발명의 하나 이상의 실시예들에 따르면, 수용성으로 전환된 트리소듐 클로린 e6 용액에 산, 염기 존재 및 특정 pH 조건에서 트리소듐 클로린 e6와 PVP의 복합체로 전환하는 과정을 수행하며 특정 동결건조 조건을 이용하여 식품과 의약품에 사용 가능한 복합체로 건조되는 효과를 얻는다.Further, according to one or more embodiments of the present invention, a trisodium chlorine e6 solution converted to water-soluble is subjected to a process of converting to a complex of trisodium chlorine e6 and PVP in the presence of an acid, a base, and at specific pH conditions and performing specific lyophilization Conditions are used to achieve the effect of drying into complexes usable for food and medicine.
또한, 본 발명의 하나 이상의 실시예들에 따르면, 전환된 트리소듐 클로린 e6을 멸균 및 여과 후에 동결 건조하여 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP의 복합체의 파우더 형태로 전환하여 식품과 의약품에 사용 가능한 복합체를 생산함으로써 제조 수율을 향상시키는 효과를 얻는다.Further, according to one or more embodiments of the present invention, the converted trisodium chlorine e6 is sterilized and filtered and then lyophilized to be converted into a powder form of a complex of high purity trisodium chlorin e6 and PVP to food and pharmaceuticals. The effect of improving the production yield is obtained by producing a composite usable in
따라서, 본 발명의 하나 이상의 실시예들에 따르면, 고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP의 복합체의 대량생산이 가능하다.Accordingly, according to one or more embodiments of the present invention, mass production of a complex of high purity trisodium chlorin e6 and PVP is possible.
도 1은 본 발명의 일 실시예에 따라 제조된 클로로필 추출물에 대한 HPLC 분석 결과를 나타낸 것이다. Figure 1 shows the HPLC analysis of the chlorophyll extract prepared according to an embodiment of the present invention.
도 2는 본 발명의 일 실시예에 따라 제조된 고순도 클로로필 추출물에 대한 HPLC 분석 결과를 나타낸 것이다.Figure 2 shows the HPLC analysis of the high purity chlorophyll extract prepared according to an embodiment of the present invention.
도 3은 본 발명의 일 실시예에 따라 제조된 페오피틴에 대한 HPLC 분석 결과를 나타낸 것이다.Figure 3 shows the results of HPLC analysis for pheophytin prepared according to an embodiment of the present invention.
도 4는 본 발명의 일 실시예에 따라 제조된 고순도 클로린 e6(Chlorin e6)의 핵자기공명(NMR) 분석 결과를 나타낸 것이다.Figure 4 shows the results of nuclear magnetic resonance (NMR) analysis of high purity Chlorin e6 (Chlorin e6) prepared according to an embodiment of the present invention.
도 5는 본 발명의 일 실시예에 따라 제조된 클로린 e6(Chlorin e6)의 HPLC 분석 결과를 나타낸 것이다.Figure 5 shows the results of HPLC analysis of Chlorin e6 (Chlorin e6) prepared according to an embodiment of the present invention.
도 6은 본 발명의 일 실시예에 따라 제조된 클로린 e6(Chlorin e6)의 액체 크로마토그래피 질량분석법 (Liquid Chromatography Mass Spectrometry LC/MS) 분석 결과를 나타낸 것이다.FIG. 6 shows the results of Liquid Chromatography Mass Spectrometry LC / MS analysis of Chlorin e6 prepared according to one embodiment of the present invention.
도 7은 본 발명의 일 실시예에 따라 제조된 고순도 트리소듐 클로린 e6(trisodium Chlorin e6) (sample)와 상용화된 제품(standard - Frontiers)의 HPLC 비교 분석 결과를 나타낸 것이다.FIG. 7 shows the results of HPLC comparison analysis of a high purity trisodium chlorin e6 (sample) prepared in accordance with an embodiment of the present invention and a commercial product (standard-Frontiers).
도 8은 본 발명의 일 실시예에 따라 제조된 트리소듐 클로린 e6(trisodium Chlorin e6) 와 분자량 10,000 이하 PVP 복합체의 자외가시부 흡광도 측정법의 측정 결과를 나타낸 것이다. Figure 8 shows the measurement results of the ultraviolet visible absorbance measurement method of trisodium chlorin e6 (trisodium Chlorin e6) and the molecular weight of 10,000 or less PVP composite prepared according to an embodiment of the present invention.
도 9는 본 발명의 일 실시예에 따른 트리소듐 클로린 e6(trisodium Chlorin e6) 의 함량을 계산하는 수식을 나타낸 것이다.Figure 9 shows the formula for calculating the content of trisodium Chlorin e6 (trisodium Chlorin e6) according to an embodiment of the present invention.
도 10은 본 발명의 일 실시예에 따른 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP 복합체에서 UV/VIS Spectrophotometry를 이용한 흡광도 비교 분석 결과를 나타낸 것이다.FIG. 10 shows the results of comparative absorbance analysis using UV / VIS Spectrophotometry in trisodium chlorin e6 and PVP composite according to an embodiment of the present invention.
이하, 실시예를 통해 본 발명의 구성 및 효과를 보다 더 구체적으로 설명하고자 하나, 이들 실시예는 본 발명의 예시적인 기재일뿐 본 발명의 범위가 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail with reference to examples, but these examples are merely illustrative of the present invention, and the scope of the present invention is not limited only to these examples.
본 명세서에서 사용된 용어는 실시예들을 설명하기 위한 것이며 본 발명을 제한하고자 하는 것은 아니다. 본 명세서에서, 단수형은 문구에서 특별히 언급하지 않는 한 복수형도 포함한다. 명세서에서 사용되는 '포함한다(comprises)' 및/또는 '포함하는(comprising)'은 언급된 구성요소는 하나 이상의 다른 구성요소의 존재 또는 추가를 배제하지 않는다.The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In this specification, the singular also includes the plural unless specifically stated otherwise in the phrase. As used herein, the words 'comprises' and / or 'comprising' do not exclude the presence or addition of one or more other components.
본원 명세서에서 용어 "암" 및 "종양"은 통상적으로 제어되지 않은 세포 성장을 특징으로 하는 포유동물에서의 생리학적 병증을 의미하거나 기술한다. 양성 및 악성 암, 및 휴면 종양 또는 미소전이가 이 정의에 포함된다. 암의 예는 암종, 림프종, 아세포종, 육종 및 백혈병을 포함하지만, 이들로 제한되지는 않는다. 이러한 암의 다른 예는 피부암, 구순암, 흑색종(피부전이), 유방암(피부전이), 피부기저세포암, 변형성 피부암, 피부편평상피세포암, 및 아랫입술의 편평세포암을 포함하지만, 이들로 제한 되지는 않는다. 또 다른 암의 예는 유방암, 편평세포암, 폐암(소세포 폐암, 비소세포 폐암, 폐의 선암 및 폐의 편평 암종 포함), 전신경 교모세포종, 신경 교모세포종, 전형적 교모세포종 및 중간엽 교모세포종, 복막의 암, 위장암, 위암(위장관암 포함), 췌장암, 난소암, 자궁경부암, 간암, 방광암, 대장암, 대장직장암, 자궁내 막암, 자궁 암종, 침샘 암종, 신장암, 전립선암, 음문암, 갑상선암, 다양한 유형의 두경부암, B 세포 림프종(저등급/여포성 비호지킨 림프종(non-Hodgkin's lymphoma: NHL); 소림프성 (small lymphocytic: SL) NHL; 중등급/여포성 NHL; 중등급 미만성 NHL; 고등급 면역아구성 NHL; 고등급 림프아 구성 NHL; 고등급 작은 비분할 세포 NHL; 벌키 질환 NHL; 외투 세포 림프종; AIDS 관련 림프종; 및 발덴스트롬 거대글로불린혈증 포함), 만성 림프성 백혈병(chronic lymphocytic leukemia: CLL), 급성 림프아구성 백혈병 (acute lymphoblastic leukemia: ALL), 모발 세포 백혈병, 만성 골수아구성 백혈병, 이식 후 림프증식성 장 애(post-transplant lymphoproliferative disorder: PTLD), , 모반증과 연관된 이상 혈관 증식, 부종(예컨대, 뇌 종양과 연관된 것), 및 메이그스 증후군(Meigs' syndrome)을 포함한다.As used herein, the terms “cancer” and “tumor” generally mean or describe physiological conditions in a mammal characterized by uncontrolled cell growth. Benign and malignant cancers, and dormant tumors or micrometastases are included in this definition. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Other examples of such cancers include skin cancer, cleft lip cancer, melanoma (skin metastasis), breast cancer (skin metastasis), skin basal cell cancer, deformed skin cancer, skin squamous cell carcinoma, and squamous cell carcinoma of the lower lip. It is not limited to. Examples of other cancers include breast cancer, squamous cell cancer, lung cancer (including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma and squamous carcinoma of the lung), systemic glioblastoma, glioblastoma, typical glioblastoma and mesenchymal glioblastoma, Cancer of the peritoneum, gastric cancer, gastric cancer (including gastrointestinal cancer), pancreatic cancer, ovarian cancer, cervical cancer, liver cancer, bladder cancer, colon cancer, colorectal cancer, endometrial cancer, uterine carcinoma, salivary gland carcinoma, kidney cancer, prostate cancer, vulvar cancer , Thyroid cancer, various types of head and neck cancer, B cell lymphoma (non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; medium / follicular NHL; medium grade) Diffuse NHL; High Grade Immunoblastic NHL; High Grade Lymphoblastic NHL; High Grade Small Non-dividing Cell NHL; Bulky Disease NHL; Mantle Cell Lymphoma; AIDS-Related Lymphoma; and Valdenstrom Giant Globulinemia), Chronic Lymphocytic Leukemia (chronic lymphocytic leukemia: CLL), Acute lymphoblastic leukemia (ALL), hair cell leukemia, chronic myeloblastic leukemia, post-transplant lymphoproliferative disorder (PTLD), abnormal blood vessel proliferation associated with nevus, edema (Eg, those associated with brain tumors), and Meigs' syndrome.
또한, 본 명세서에 사용되는 바와 같은 "암" 및 "종양"은 모든 신생 세포 성장 및 증식(악성이든 또는 양성이든), 및 모든 전암성 및 암성 세포 및 조직을 의미한다. 용어 "암", "암성", "세포 증식성 장애", "증식성 장애" 및 "종양"은 본 명세서에 언급되는 것으로 상호 배타적이지 않다.Also, as used herein, "cancer" and "tumor" refer to all neoplastic growth and proliferation (either malignant or benign), and all precancerous and cancerous cells and tissues. The terms "cancer", "cancerous", "cell proliferative disorder", "proliferative disorder" and "tumor" are referred to herein and are not mutually exclusive.
본원 명세서에서, 용어 ‘클로린 이 식스’는 ‘Chlorin e6’ 또는 ‘클로린 e6’로 표시될 수 있다.In the present specification, the term 'chlorine e six' may be represented by 'Chlorin e6' or 'chlorine e6'.
본원 명세서에서, 용어 '복합체'는 트리소듐 Chlorin e6(trisodium Chlorin e6)와 분자량 15,000 이하 폴리비닐피롤리돈(이하, "PVP")(polyvinylpyrrolidone)의 복합체를 의미하는 것으로 사용하기로 한다.In the present specification, the term 'composite' is used to mean a complex of trisodium Chlorin e6 and polyvinylpyrrolidone (hereinafter referred to as "PVP") (polyvinylpyrrolidone) having a molecular weight of 15,000 or less.
본 발명의 실시예에 따라서 제조된 트리소듐 Chlorin e6(trisodium Chlorin e6)와 PVP(polyvinylpyrrolidone)의 복합체는, 광역학적으로 암을 치료하기 위한 약학적 조성물로 사용될 수 있다.The complex of trisodium Chlorin e6 and trivinylpyrrolidone (PVP) prepared according to an embodiment of the present invention may be used as a pharmaceutical composition for treating cancer photodynamically.
본 발명의 일 실시예에 따르면, 트리소듐 Chlorin e6와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법은, Chlorin e6, PVP (polyvinylpyrrolidone), NaOH, 및 HCl을 혼합하는 단계와 상기 혼합하는 단계의 수행 결과물을 동결 건조시켜 분말로 만드는 단계를 포함한다. According to one embodiment of the present invention, trisodium Chlorin e6 and PVP (polyvinylpyrrolidone) composite production method, Chlorin e6, polyvinylpyrrolidone (PVP), NaOH, HCl and the result of the step of mixing the frozen result Drying to powder.
본 실시예에서, Chlorin e6 는 다음의 구조In this embodiment, Chlorin e6 has the structure
를 가지며, 분자식(molecular formula) C34H36N4O6 로 표현된다.It is represented by the molecular formula C 34 H 36 N 4 O 6 .
본 실시예에서, 혼합하는 단계는 다음의 구조In this embodiment, the mixing step has the following structure
를 가지며 분자식 C34Н33О6N4Na3로 표현되는 트리소듐 Chlorin e6와 상기 PVP(polyvinylpyrrolidone)의 복합체를 생성하는 단계이다. It is a step of generating a complex of trisodium Chlorin e6 and the polyvinylpyrrolidone (PVP) having a molecular formula C 34 Н 33 О 6 N 4 Na 3 .
제1실시예First embodiment
제1실시예에 따르면, 트리소듐 Chlorin e6와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법은, Chlorin e6를 멸균 및 여과시키는 단계(S50), Chlorin e6, PVP (polyvinylpyrrolidone), NaOH, 및 HCl을 혼합하는 단계(S100), 및 상기 혼합하는 단계의 수행 결과물을 동결 건조시켜 분말로 만드는 단계(S110)를 포함한다. According to the first embodiment, the method for producing a complex of trisodium Chlorin e6 and polyvinylpyrrolidone (PVP), sterilizing and filtering Chlorin e6 (S50), mixing Chlorin e6, polyvinylpyrrolidone (PVP), NaOH, and HCl (S100), and lyophilizing the resultant of the performing of the step of mixing to make a powder (S110).
즉, 제1실시예에 따르면, 혼합하는 단계(S100)를 수행하기 전에, Chlorin e6를 멸균 및 여과시키는 단계(S50)를 수행한다. That is, according to the first embodiment, before performing the mixing step (S100), the step of sterilizing and filtering Chlorin e6 (S50) is performed.
제1실시예에 따르면, 멸균 및 여과 시키는 단계(S50)는, Chlorin e6를 물에 용해시키고, 용해물의 pH를 7 보다 적도록 pH를 조절하는 제1 pH 조절단계; pH가 7 보다 적은 용해물의 pH를 7 이상으로 pH를 조절하는 제2 pH 조절단계; 및 pH가 7 이상인 상기 용해물을 마이크로 필터를 이용하여 멸균 및 여과시키는 단계;를 포함한다. 여기서, 마이크로 필터는 예를 들면, 0.22㎛ 직경을 가진 것일 수 있으나 이러한 수치는 예시적인 것이다.According to a first embodiment, the step of sterilization and filtration (S50), the first pH adjustment step of dissolving Chlorin e6 in water, adjusting the pH to less than 7 pH of the lysate; a second pH adjusting step of adjusting the pH of the lysate having a pH less than 7 to 7 or more; And sterilizing and filtering the lysate having a pH of 7 or more using a micro filter. Here, the micro filter may be, for example, having a diameter of 0.22 μm, but this value is exemplary.
제1실시예에 따르면, 예를 들면, 제1 pH 조절단계는 용해물의 pH를 2로 조절하는 단계이고, 제2 pH 조절단계는 상기 용해물의 pH를 7.1로 조절하는 단계이다. According to the first embodiment, for example, the first pH adjusting step is adjusting the pH of the lysate to 2, and the second pH adjusting step is adjusting the pH of the lysate to 7.1.
제1실시예에 따르면, 혼합하는 단계(S100)는 혼합하는 단계(S100)의 수행결과인 혼합물의 pH를 7 내지 9로 조절하는 단계를 포함한다. According to the first embodiment, the mixing step (S100) includes adjusting the pH of the mixture as a result of performing the mixing step (S100) to 7 to 9.
제1실시예에 따르면, 혼합하는 단계(S100)는, 혼합하는 단계(S100)의 수행결과인 혼합물의 pH를 7 내지 9로 조절하는 단계와 마이크로 필터를 이용하여 혼합물을 멸균 및 여과시키는 단계를 포함하도록 구현될 수 있다. According to the first embodiment, the mixing step (S100), the step of adjusting the pH of the mixture resulting from the mixing step (S100) to 7 to 9 and sterilizing and filtering the mixture using a micro filter It can be implemented to include.
제1실시예에 따르면, 혼합하는 단계(S100)는 혼합물에서 NaCl의 중량 퍼센트가 5% 이하가 되도록 수행될 수 있다.According to the first embodiment, the mixing step S100 may be performed such that the weight percentage of NaCl in the mixture is 5% or less.
제2실시예Second embodiment
제2실시예에 따르면, Chlorin e6, PVP (polyvinylpyrrolidone), NaOH, 및 HCl을 혼합하는 단계(S100), 및 상기 혼합하는 단계의 수행 결과물을 동결 건조시켜 분말로 만드는 단계(S110)를 포함하고, 여기서 혼합하는 단계(S110)는 혼합하는 단계(S110)의 수행결과인 혼합물의 pH를 7 내지 9로 조절하는 단계와 마이크로 필터를 이용하여 혼합물을 멸균 및 여과시키는 단계를 포함한다. 마이크로 필터는 예를 들면, 0.22㎛ 직경을 가진 것일 수 있으나 이러한 수치는 예시적인 것이다.According to a second embodiment, the step of mixing Chlorin e6, polyvinylpyrrolidone (PVP), NaOH, and HCl (S100), and lyophilizing the resultant of the mixing step to make a powder (S110), Here, the mixing step S110 may include adjusting the pH of the mixture resulting from the mixing step S110 to 7 to 9 and sterilizing and filtering the mixture using a micro filter. The micro filter may be, for example, having a diameter of 0.22 μm but this value is exemplary.
제2실시예에 따르면, 혼합하는 단계(S100)는 혼합물에서 NaCl의 중량 퍼센트가 5% 이하가 되도록 수행될 수 있다.According to the second embodiment, the mixing step S100 may be performed such that the weight percentage of NaCl in the mixture is 5% or less.
본원 명세서에서, 용어 '복합체'라고 함은 트리소듐 Chlorin e6와 PVP(polyvinylpyrrolidone)의 복합체를 의미한다. As used herein, the term 'composite' refers to a complex of trisodium Chlorin e6 and polyvinylpyrrolidone (PVP).
본 발명의 일 실시예에 따른 복합체는, 트리소듐 Chlorin e6와 PVP(polyvinylpyrrolidone)가 1:9, 5:5, 4:6, 또는 6:4, 9:1로 구성된 것일 수 있다. 이러한 수치는 예시적인 것이므로 본원 발명의 권리범위가 그러한 수치에만 한정되는 것은 아니다. In the composite according to an embodiment of the present invention, trisodium chlorin e6 and polyvinylpyrrolidone (PVP) may be composed of 1: 9, 5: 5, 4: 6, or 6: 4, 9: 1. These figures are exemplary, and the scope of the present invention is not limited only to those figures.
본 발명의 실시예들에 따르면, 혼합하는 단계(S100)는, 혼합하는 단계의 수행결과인 혼합물의 PH가 7 - 9가 되도록 수행된다. According to embodiments of the present invention, the mixing step S100 is performed such that the pH of the mixture, which is a result of performing the mixing step, becomes 7-9.
한편, 혼합하는 단계(S100)는On the other hand, the mixing step (S100)
또는 or
와 같이 표현될 수 있다. It can be expressed as
본 발명의 일 실시예에 따르면, 혼합하는 단계(S100)는, According to one embodiment of the invention, the mixing step (S100),
Chlorin e6와 분자량 15,000 이하 PVP(polyvinylpyrrolidone)를 먼저 혼합시키고 난 후, Chlorin e6와 PVP(polyvinylpyrrolidone)의 혼합물과 NaOH와 HCl을 혼합시키는 방법으로 구현될 수 있다. 여기서, NaOH와 HCl의 몰수는 혼합하는 단계의 결과물의 PH가 7 내지 9가 되도록 정해진다.Chlorin e6 and a molecular weight of 15,000 or less polyvinylpyrrolidone (PVP) may be mixed first, and then a mixture of chlorin e6 and polyvinylpyrrolidone (PVP) may be implemented by mixing NaOH and HCl. Here, the number of moles of NaOH and HCl is set so that the pH of the result of the mixing step is 7 to 9.
본 발명의 다른 실시예에 따르면, 혼합하는 단계(S100)는 According to another embodiment of the present invention, the mixing step (S100) is
Chlorin e6와 NaOH와 HCl를 먼저 혼합시키고 난 후, Chlorin e6와 NaOH와 HCl의 혼합물과 PVP(polyvinylpyrrolidone)를 혼합시키는 방법으로 구현될 수 있다. 여기서, NaOH와 HCl의 몰수는 혼합하는 단계의 결과물의 PH가 7 내지 9가 되도록 정해진다.Chlorin e6 and NaOH and HCl may be mixed first, and then a mixture of Chlorin e6 and NaOH and HCl and polyvinylpyrrolidone (PVP) may be implemented. Here, the number of moles of NaOH and HCl is set so that the pH of the result of the mixing step is 7 to 9.
본 발명의 또 다른 실시예에 따르면, 혼합하는 단계(S100)는According to another embodiment of the present invention, the mixing step (S100)
Chlorin e6와 NaOH와 HCl와 PVP(polyvinylpyrrolidone)를 동시에 혼합시키고, 혼합물의 PH가 7 내지 9가 되도록 하는 방법으로 구현될 수 있다. Chlorin e6 and NaOH and HCl and PVP (polyvinylpyrrolidone) may be mixed at the same time, the pH of the mixture can be implemented by a method of 7 to 9.
이하에서는, 본 발명의 일 실시예에 따른 Chlorin e6를 제조하는 방법을 설명하기로 한다. 본 방법에 따라 제조된 Chlorin e6는 상술한 복합체를 제조하는데 사용될 수 있다. Hereinafter, a method of preparing chlorin e6 according to an embodiment of the present invention will be described. Chlorin e6 prepared according to the present method can be used to prepare the complexes described above.
본 발명의 일 실시예에 따른 Chlorin e6를 제조하는 방법은, 클로로필을 함유하는 녹색식물 또는 미세조류를 메탄올, 에탄올, 아세톤 또는 이들 각각의 수용액에 넣어 클로로필 추출물을 추출하는 단계, 클로로필 추출물에 헥산과 물을 넣고 교반하는 단계, 교반된 용액에서 헥산층을 분리하여 클로로필을 정제하는 단계, 정제된 클로로필을 메탄올, 에탄올, 아세톤 및 이들의 혼합용매 중 어느 하나의 용매에 용해시킨 후, 산을 첨가하여 산성화하는 단계, 산성화하는 단계의 수행 결과물에 물을 첨가하여 페오피틴(pheophytin) 침전물을 획득하는 단계, 및 페오피틴 침전물을 아세톤에 용해시키고 염기를 첨가하여 클로린 e6을 생성하는 단계를 포함한다.Method for preparing chlorin e6 according to an embodiment of the present invention, the green plant or microalgae containing chlorophyll in a methanol, ethanol, acetone or each of these aqueous solution to extract the chlorophyll extract, chlorophyll extract hexane and Adding water and stirring, separating the hexane layer from the stirred solution to purify the chlorophyll, dissolving the purified chlorophyll in a solvent of any one of methanol, ethanol, acetone and a mixed solvent thereof, and then adding an acid. Acidifying, adding water to the result of the acidifying step to obtain a pheophytin precipitate, and dissolving the pheophytin precipitate in acetone and adding a base to produce chlorine e6. .
본 실시예에 따르면, 추출하는 단계는, 녹색식물 또는 미세조류를 메탄올, 에탄올, 아세톤 또는 이들 각각의 수용액에 넣는 단계와 수용액에 초음파를 가하는 단계를 포함할 수 있다. 여기서, 초음파는 주파수가 10 내지 50 kHz 일 수 있다. According to the present embodiment, the extracting may include adding green plants or microalgae to methanol, ethanol, acetone or their respective aqueous solutions, and applying ultrasonic waves to the aqueous solutions. Here, the ultrasound may have a frequency of 10 to 50 kHz.
본 실시예는, 교반하는 단계의 수행 전에, 추출하는 단계의 수행 결과물을 필터를 이용하여 분리 농축시키는 단계를 더 포함할 수 있다. The present embodiment may further include a step of separating and concentrating the result of performing the extracting step using a filter before performing the stirring step.
본 실시예에 따르면, 교반하는 단계는 클로로필 추출물에 헥산과 물을 넣어 제1 혼합물을 생성하는 단계와 혼합물에 초음파를 가하면서 제1 혼합물을 교반시키는 단계를 포함할 수 있다. 여기서, 초음파는 주파수가 10 내지 50 kHz 일 수 있다.According to this embodiment, the stirring may include adding hexane and water to the chlorophyll extract to generate a first mixture, and stirring the first mixture while applying ultrasonic waves to the mixture. Here, the ultrasound may have a frequency of 10 to 50 kHz.
이하에서는, 본 발명의 일 실시예에 따른 트리소듐 Chlorin e6와 PVP(polyvinylpyrrolidone)의 복합체 제조 방법과 Chlorin e6를 제조하는 방법을 구체적으로 설명하기로 한다.Hereinafter, a method for preparing a complex of trisodium chlorin e6 and polyvinylpyrrolidone (PVP) and a method for producing chlorin e6 according to an embodiment of the present invention will be described in detail.
클로로필의 추출 및 정제 방법Chlorophyll Extraction and Purification Methods
본 발명의 일 실시예에 따른 클로로필 a와 b의 추출 및 정제 방법에 따라 추출 및 정제된 클로로필 a와 b는 상술한 복합체를 제조하는데 사용될 수 있다. Chlorophyll a and b extracted and purified according to the method for extracting and purifying chlorophyll a and b according to an embodiment of the present invention may be used to prepare the above-mentioned complex.
본 방법에 따르면, 스피루리나를 함유하는 녹색식물 또는 미세조류를 동적 복합파장 초음파 추출기술을 이용하여 클로로필을 추출하여 획득하는 방법이다.According to this method, a green plant or microalgae containing spirulina is obtained by extracting chlorophyll using a dynamic compound wavelength ultrasonic extraction technique.
본 방법에 따르면, 클로로필 수득에 사용된 녹색 식물 또는 미세조류의 선택에 특별한 제한을 두고 있지 않으며, 클로로필을 함유하는 모든 식물 또는 미세조류라면 모두 적용될 수 있다. According to the method, no particular limitation is placed on the selection of the green plant or microalgae used to obtain chlorophyll, and any plant or microalgae containing chlorophyll may be applied.
본 방법에 따르면, 녹색식물 또는 미세조류를 물, 메탄올, 에탄올, 아세톤 및 이의 수용액과 같이 극성이 상대적으로 큰 용매를 교반하고, 교반물에 초음파 추출 방법을 적용한다. 그리고, 초음파 추출 방법을 적용한 결과물에 다공성 알루미나 세라믹 필터 (5-20μm)를 적용하여 분리 및 농축하여 클로로필 추출물을 얻는다. 이후, 클로로필에 대한 용해도가 높고 극성이 비교적 낮은 헥산을 상기 클로로필 추출물에 첨가한다. 그리고, 상기 헥산이 첨가된 클로로필 추출물에 초음파 추출 및 교반 과정을 적용 하여 클로로필을 최대한 헥산 층으로 이동시킨다. 이후,상기 초음파 추출 및 교반 과정이 적용된 결과물에 물을 첨가하고 교반하면 헥산 층에 포함될 수 있는 클로로필 이외의 불순물은 물 층으로 이동됨으로써 고순도의 클로로필을 헥산 층에서 얻는다.According to the present method, green plants or microalgae are stirred with a solvent having a relatively high polarity, such as water, methanol, ethanol, acetone, and an aqueous solution thereof, and an ultrasonic extraction method is applied to the stirred solution. In addition, a porous alumina ceramic filter (5-20 μm) is applied to the resultant obtained by applying the ultrasonic extraction method, and separated and concentrated to obtain a chlorophyll extract. Then, hexane with high solubility in chlorophyll and relatively low polarity is added to the chlorophyll extract. The chlorophyll extract to which hexane is added is subjected to ultrasonic extraction and stirring to move the chlorophyll to the hexane layer as much as possible. Thereafter, when water is added to the resultant to which the ultrasonic extraction and stirring process is applied and stirred, impurities other than chlorophyll, which may be included in the hexane layer, are transferred to the water layer, thereby obtaining high purity chlorophyll from the hexane layer.
본 방법에 따르면, 헥산은 클로로필과 같은 비극성 특성을 가지고 있어 클로로필에 대한 용해도가 높을 뿐만 아니라, 헥산은 메탄올, 에탄올, 아세톤 또는 이들 각각의 수용액과 서로 섞이지 않고 층 분리되는 특성을 가지고 있다. 따라서, 클로로필 추출물을 초음파, 헥산과 물을 사용하여 정제함으로써 클로로필은 헥산 층에 보다 쉽게 용해되어 분포하게 되고, 클로로필 이외의 불순물은 물, 메탄올, 에탄올 또는 아세톤 층으로 보다 쉽게 층 분리되어 분포하게 되므로, 고순도의 클로로필 수득이 가능하다. According to the method, hexane has a nonpolar characteristic such as chlorophyll, so that it has high solubility in chlorophyll, and hexane has a property of being separated without mixing with methanol, ethanol, acetone or their respective aqueous solutions. Therefore, by purifying chlorophyll extract using ultrasonic wave, hexane and water, chlorophyll is more easily dissolved and distributed in the hexane layer, and impurities other than chlorophyll are easily separated and distributed into water, methanol, ethanol or acetone layers. It is possible to obtain high purity chlorophyll.
본 방법에 따르면, 스피루리나에서 클로로필 추출시 사용되는 초음파는 10-50 kHz, 100-500 W로 조절가능하며, 추출율 100% 도달에 걸리는 시간이 최대 2시간으로서 기존 6시간 - 12시간보다 매우 효과적이며 경제적이다. According to the method, the ultrasonic wave used to extract chlorophyll in spirulina can be adjusted to 10-50 kHz, 100-500 W, and the time taken to reach 100% extraction rate is up to 2 hours, which is more effective than the existing 6 to 12 hours. It is economical.
본 방법에 따르면, 클로로필 추출용매로서 메탄올, 에탄올, 아세톤 또는 이들 각각의 수용액을 사용하는 경우, 추출용매 중의 물 함유량은 30 부피% 미만으로 조절 가능하다. 그 이유는 초음파 추출 장비를 사용하게 되면 짧은 시간내에 클로로필의 추출이 가능해 클로로필의 분해 및 변성을 방지할 수 있기 때문이다. According to this method, when methanol, ethanol, acetone or their respective aqueous solutions are used as the chlorophyll extractant, the water content in the extractant can be adjusted to less than 30% by volume. The reason is that the use of ultrasonic extraction equipment enables the extraction of chlorophyll in a short time, thereby preventing the decomposition and denaturation of chlorophyll.
본 방법에 따르면, 초음파와 함께 사용되는 정제용매 헥산은, 농축된 클로로필 추출물의 부피에 대하여 최대 3배 내로 줄이며 사용 가능하다. 초음파가 사용되면 상대적으로 적은 양의 헥산으로 클로로필이 헥산 층으로 쉽게 이동하여 경제적으로 클로로필의 수율을 증가시킬 수 있게 된다. 초음파를 동반한 헥산에 의한 추출과정에서 교반시간은 1 시간 이내이며, 초음파를 사용하지 않는 경우 교반시간 3시간 보다 단축하게 된다.According to the method, the purified solvent hexane used in conjunction with the ultrasonic wave can be reduced to within 3 times the volume of the concentrated chlorophyll extract. The use of ultrasound allows the chlorophyll to move easily into the hexane layer with a relatively small amount of hexane, thereby economically increasing the yield of chlorophyll. In the extraction process with hexane accompanied by ultrasonic waves, the stirring time is less than 1 hour, and when ultrasonic waves are not used, the stirring time is shorter than 3 hours.
또한, 본 방법에 따르면, 헥산을 클로로필 추출물에 첨가한 후에, 추가로 초음파 및 물을 이용하여 클로로필을 추출하게 되면 클로로필의 정제효과는 보다 극대화될 수 있다. 즉 초음파 처리와 물을 첨가하여 불순물을 수층으로 쉽게 이동시켜 헥산 층으로부터 고순도의 클로로필을 얻을 수 있다. 이때 다공성 알루미나 세라믹 필터 (5-20 μm)를 이용한 여과 공정을 수행할 수 있다. 초음파의 주파수는 10 내지 50kHz이고, 전력은 100 내지 500W로 조절되며 5분 내지 10분 이내와 같이 짧은 시간 처리하는 것이 좋다. 이 과정에서 초음파를 사용함으로써 에멀젼 형성을 방지할 수 있으므로 경제적이다. In addition, according to the method, after the addition of hexane to the chlorophyll extract, if the chlorophyll is further extracted by using ultrasonic waves and water can be further maximized the purification effect of chlorophyll. That is, it is possible to easily transfer impurities to the aqueous layer by sonication and water to obtain high purity chlorophyll from the hexane layer. In this case, a filtration process using a porous alumina ceramic filter (5-20 μm) may be performed. The frequency of the ultrasonic wave is 10 to 50 kHz, the power is adjusted to 100 to 500 W, and a short time treatment such as within 5 to 10 minutes is preferable. The use of ultrasonic waves in this process is economical since emulsion formation can be prevented.
이상 설명한 본 발명에 따른 클로로필의 추출 및 정제 방법은, 종래 3일의 공정기간을 12시간 이내로 단축 가능하며 정제된 클로로필 a와 b는 90% 이상의 순도를 가진다. In the method for extracting and purifying chlorophyll according to the present invention described above, the conventional three-day process period can be shortened within 12 hours, and the purified chlorophyll a and b have a purity of 90% or more.
페오피틴 합성 방법Pheophytin Synthesis Method
본 방법은 본 발명의 일 실시예에 따른 페오피틴 수득 방법이다. This method is a method for obtaining pheophytin according to an embodiment of the present invention.
본 방법에 따르면, 하기 화학식 1로 표시되는 클로로필 a를 산으로 처리하여 마그네슘이 제거된 하기 화학식 2로 표시되는 페오피틴을 수득한다.According to the present method, chlorophyll-a represented by the following formula (1) is treated with an acid to obtain a phephytin represented by the following formula (2) from which magnesium is removed.
<화학식 1><
<화학식 2><
본 방법에 따르면, 클로로필을 용매에 용해시킨 후에, 산을 첨가하고 초음파 처리 (10 내지 50kHz, 100 내지 500 W로 조절 가능) 및 상온 교반한다. 이에 의해 클로로필 분자 내에 포함된 마그네슘 원자가 탈리 되어, 30분 내지 1시간 이내에 페오피틴으로 전환시킨다.According to the method, after the chlorophyll is dissolved in the solvent, the acid is added and sonicated (10-50 kHz, adjustable to 100-500 W) and stirred at room temperature. As a result, the magnesium atom contained in the chlorophyll molecule is released and converted into phefitin within 30 minutes to 1 hour.
본 방법에 따르면, 마그네슘 탈리를 위해 첨가하는 산은 클로로필 한 분자당 3 당량 이내이며, 반응용액의 pH는 1 내지 3의 범위로 조절된다. 이때 사용되는 산의 첨가량은 초음파 처리와 더불어 소량 사용되므로 경제적이며, 과다반응으로 인한 페오포비드 부산물 형성을 방지할 수 있는 특징이 있다. 마그네슘 탈리를 위해 첨가되는 산의 종류에 대해 특별한 제약은 없으며, 염산, 황산, 또는 인산 등의 통상의 무기산 또는 아세트산 등과 같은 유기산으로부터 선택하여 사용될 수 있다. According to this method, the acid added for magnesium desorption is within 3 equivalents per molecule of chlorophyll, and the pH of the reaction solution is adjusted in the range of 1 to 3. At this time, the amount of acid used is economical because it is used in a small amount together with the sonication, and there is a characteristic that can prevent the formation of the pheopovid by-products due to overreaction. There is no particular restriction on the kind of acid added for the desorption of magnesium, and it may be selected from conventional inorganic acids such as hydrochloric acid, sulfuric acid, or phosphoric acid, or organic acids such as acetic acid and the like.
본 방법에 따르면, 초음파 처리와 더불어 산을 첨가하여 생성된 페오피틴을 경제적으로 고순도로 분리 정제함으로써 중간물질 클로린 e6의 순도를 높일 수 있다.According to this method, the purity of the intermediate chlorine e6 can be increased by economically separating and purifying the pheophytin produced by adding acid in addition to sonication economically.
본 방법에 따르면, 상술한 바와 같이 초음파 처리 및 산 처리하여 생성된 페오피틴은 다공성 알루미나 세라믹필터 (5-20 μm)에 의해 여과된다. 그리고, 여과된 페오피틴 침전물을 -20℃ ~ -40℃의 저온 및 20mbar의 저압으로 유지하면서 냉각시키고 콜드트랩 (-70℃ ~ -80℃)을 이용하여 수분을 제거한다. 상술한 범위의 저온 및 저압에서는 수분이 증기상태로 승화되어 제거될 수 있는 진공상태가 형성된다. 이처럼, 동결상태에서 승화 건조되므로 페오피틴 입자 표면이 경화되거나 수축되지 않는다. 많은 신약은 과도한 건조에 의해 피해 입을 수 있으므로 최종 수분의 양이1.5% - 2.0%사이에서 건조 됐을 때 최고의 적정량으로 유지된다. According to the method, the pheophytin produced by sonication and acid treatment as described above is filtered by a porous alumina ceramic filter (5-20 μm). The filtered pheophytin precipitate is then cooled while maintaining at a low temperature of -20 ° C to -40 ° C and a low pressure of 20mbar and water is removed using a cold trap (-70 ° C to -80 ° C). At low temperature and low pressure in the above-described range, a vacuum state is formed in which moisture can be sublimed and removed. As such, sublimation drying in the frozen state does not cure or shrink the surface of the pheophytin particles. Many new drugs can be damaged by overdrying, so the final amount of water is maintained at the best level when the final moisture is dried between 1.5% and 2.0%.
본 방법에 따르면 페오피틴의 정제를 위하여, 클로로필이 용해된 용액에 초음파 (10 내지 50kHz, 100 내지 500 W로 조절가능)가 가해지고 에탄올과 물을 이용하여 세척하는 동작이 수행되면, 페오피틴의 정제 효과는 보다 극대화될 수 있다. 즉, 초음파 처리와 에탄올과 물의 첨가가 이루어짐으로써, 불순물을 수용액 층으로 쉽게 이동시켜 헥산 층으로부터 고순도의 페오피틴을 얻을 수 있다. 이때 처리되는 초음파는 10 내지50kHz, 100내지 500 W로 조절 가능하며 5분 내지 10분 이내로 짧은 시간 처리하는 것이 좋다. According to the method for the purification of pheophytin, the ultrasonic wave (adjustable to 10 to 50 kHz, 100 to 500 W) is applied to the chlorophyll-dissolved solution and washing with ethanol and water is performed, The purification effect of tin can be further maximized. That is, by the sonication and the addition of ethanol and water, impurities can be easily transferred to the aqueous solution layer to obtain a high purity pheophytin from the hexane layer. In this case, the ultrasonic waves to be treated can be adjusted to 10 to 50 kHz, 100 to 500 W, and a short time is processed within 5 to 10 minutes.
이상의 산 처리 방법을 수행하고 다공성 알루미나 세라믹필터를 통해 얻은 페오피틴 침전물은 95% 이상의 순도를 가지며, 사용된 클로로필 중량에 대비하여 95% 이상의 수율로 수득된다.The pheophytin precipitate obtained through the above acid treatment method and obtained through the porous alumina ceramic filter has a purity of 95% or more and is obtained in a yield of 95% or more based on the weight of chlorophyll used.
클로린 e6 제조Chlorine e6 manufacturers
본 방법은, 본 발명의 일 실시예에 따른 클로린 e6의 제조 방법이다. This method is a method for producing chlorine e6 according to an embodiment of the present invention.
본 방법에 따르면, 페오피틴에 염기를 넣고 가열 반응시켜 하기 화학식 3으로 표시되는 클로린 e6을 수득한다.According to the method, chlorine e6 represented by the following Chemical Formula 3 is obtained by adding a base to pheophytin and heating the reaction.
<화학식 3><Formula 3>
본 방법에 따르면, 농축한 페오피틴 건조물을 아세톤으로 용해시킨다. 용해한 아세톤 용액의 잔존 수분을 Na2SO4를 이용하여 제거하고, 환류 반응 장치에 에탄올과 함께 첨가한다. 60℃ 내지 70℃ 환류하에서 수산화나트륨을 이용하여 pH를 13 이상으로 맞춘다. 이때, 염기는 통상적으로 사용되는 것으로 알칼리금속 또는 알칼리토금속의 수산화물 등의 무기 염기, 또는 암모늄염 등의 유기염기를 사용할 수 있다. pH 적정은 전위차 자동적정기를 이용하여, 실시간으로 빠르게 pH를 적정할 수 있다. According to this method, the concentrated phephytin dry matter is dissolved in acetone. The remaining moisture of the dissolved acetone solution is removed using Na 2 SO 4 , and added to the reflux reactor together with ethanol. The pH is adjusted to 13 or higher using sodium hydroxide at 60 ° C. to 70 ° C. reflux. In this case, the base is commonly used, and may be an inorganic base such as a hydroxide of an alkali metal or an alkaline earth metal, or an organic base such as an ammonium salt. pH titration can be rapidly titrated in real time using a potentiometric automatic titrator.
상기 반응이 종료된 후, 반응물로부터 다공성 알루미나 세라믹 필터(5-20 μm)를 이용하여 클로린 e6를 수득하고, 수득한 클로린 e6를 진공 및 건조 공정으로 건조한다. 이상의 방법으로 수득한 클로린 e6는 90% 이상이며 사용된 페오피틴 중량에 대비하여 90% 이상의 수율로 수득된다.After the reaction is completed, chlorine e6 is obtained from the reactants using a porous alumina ceramic filter (5-20 μm), and the obtained chlorine e6 is dried by vacuum and drying process. Chlorin e6 obtained by the above method is at least 90% and is obtained in a yield of at least 90% based on the weight of the pheophytin used.
클로린 e6 및 트리소듐 클로린 e6 정제Chlorine e6 and trisodium chlorine e6 tablets
본 방법은, 본 발명의 일 실시예에 따른 클로린 e6 정제 방법이다. This method is a chlorine e6 purification method according to an embodiment of the present invention.
본 방법에 따르면, 건조된 클로린 e6에 산처리 및 알카리 처리를 하여, 고순도 클로린 e6를 수득하는 과정이다.According to this method, it is a process of obtaining the high purity chlorine e6 by performing acid treatment and alkali treatment on the dried chlorine e6.
본 방법에 따르면, 건조한 클로린 e6를 물에 용해시킨 후, 전위차 자동적정기를 이용하여 pH를 7 내지 9까지 맞추고, 물에 용해되지 않는 미세입자를 0.22μm 마이크로필터를 이용하여 멸균여과 하면서 제거한다. 그리고, 멸균 여과된 용해물에 산처리를 하면서 전위차 자동적정기를 이용하여 상기 용해물의 pH를 2까지 조절하고 클로린 e6를 0.22 μm 마이크로필터를 이용하여 멸균 여과하여 수득한다. 클로린 e6를 정제하기 위하여 에탄올에 1% 무게비율로 넣고 1시간 이상 교반 한 후 진공건조를 통해 고순도 클로린 e6를 얻는다. 이상의 방법으로 수득한 클로린 e6는 95% 이상이다. According to the method, after dissolving the dry chlorine e6 in water, the pH is adjusted to 7-9 using a potentiometric autotitrator, and microparticles which are not dissolved in water are removed by sterile filtration using a 0.22 μm microfilter. And, while acid-treating the sterile filtered lysate, the pH of the lysate was adjusted to 2 using a potentiometric autotitrator and chlorine e6 was obtained by sterile filtration using a 0.22 μm microfilter. To purify chlorine e6, it is added to 1% by weight in ethanol and stirred for at least 1 hour, followed by vacuum drying to obtain high purity chlorine e6. Chlorine e6 obtained by the above method is 95% or more.
이후 건조된 고순도 클로린 e6를 아세톤 또는 물에 용해시킨 후, pH를 천천히 8.5에 맞추고, 0.22 μm 마이크로필터를 이용하여 멸균여과 하고 동결건조 공정으로 건조한다. 이상의 방법으로 고순도 트리소듐 클로린 e6를 얻는다.The dried high purity chlorine e6 is then dissolved in acetone or water, the pH is slowly adjusted to 8.5, sterilized using a 0.22 μm microfilter and dried by lyophilization process. By the above method, high purity trisodium chlorine e6 is obtained.
트리소듐 클로린 e6와 PVP의 복합체 제조Complex preparation of trisodium chlorine e6 with PVP
본 방법은, 본 발명의 일 실시예에 따른 트리소듐 클로린 e6와 PVP 복합체 제조 방법이다. 본 방법의 일 실시예에 따르면, 고순도 클로린 e6 또는 고순도 트리소듐 클로린 e6를 PVP와 일대일 또는 일대 십 또는 십대 일로 상온에서 수용액에 혼합하며 교반 한다. 이때 전위차 자동적정기를 이용하여 혼합물의 pH를 7 내지 9에 맞추며 NaCl 생성량이 최소로 유지되게 하여 트리소듐 클로린 e6와 PVP 복합체를 제조한다. 이 과정에서 교반은 1시간 이내로 한다. 복합체는 0.22 μm 마이크로필터로 멸균 여과된다. 이후, 멸균 여과된 복합체는 동결건조를 위하여, -20℃ 내지 -40℃의 저온과 20 mbar의 저압을 유지하면서 냉각시키고 콜드트랩 (-70℃ 내지 -80℃)을 이용하여 수분을 제거한다. 상술한 저온 및 저압에서는 수분이 증기상태로 승화되어 제거될 수 있는 진공상태가 된다. 동결상태에서 승화 건조되므로 복합체의 표면이 경화되거나 수축되지 않는다. The method is a method for producing trisodium chlorine e6 and PVP complex according to an embodiment of the present invention. According to one embodiment of the method, high purity chlorine e6 or high purity trisodium chlorine e6 is stirred and mixed with PVP in an aqueous solution at room temperature in one-to-one or one-to-one or teenage days. At this time, the pH of the mixture is adjusted to 7 to 9 using a potentiometric automatic titrator to maintain a minimum amount of NaCl to prepare trisodium chlorine e6 and PVP complex. In this process, stirring is carried out within 1 hour. The complex is sterile filtered with a 0.22 μm microfilter. The sterile filtered complex is then cooled for freeze-drying while maintaining a low temperature of -20 ° C to -40 ° C and a low pressure of 20 mbar and water is removed using a cold trap (-70 ° C to -80 ° C). At the low temperature and low pressure described above, the water becomes a vacuum state in which water can be sublimated and removed. Sublimation drying in the frozen state does not cure or shrink the surface of the composite.
과도한 건조에 의해 피해를 입을 수 있으므로 최종 수분의 양이 1.5% 내지 2% 사이에서 건조되도록 유지한다.The final amount of moisture is kept dry between 1.5% and 2% as damage may be caused by excessive drying.
이상에서 설명한 바와 같이, 본 발명의 실시예들에 따르면, 특정 원재료의 제약이 없이 클로로필을 함유하는 출발 물질로부터 트리소듐 클로린 e6를 경제적으로 단기공정을 적용하여 분리, 추출, 및 정제한다. As described above, according to the embodiments of the present invention, trisodium chlorine e6 is separated, extracted, and purified from a chlorophyll-containing starting material economically using a short-term process without any limitation of specific raw materials.
또한, 본 발명의 실시예들에 따르면, 원료물질에서 용매의 용해도 차이와 극성도, 초음파공정을 이용하여 클로로필 이외의 물질을 제거하는 간단하고 효율적인 방법으로 순도 높은 클로로필을 얻을 수 있다. 그리고, 이를 통해 페오피틴과 클로린 e6 합성에서는 반응 시간과 유기 용매의 양을 단축하는 경제적인 공정을 이용하고, 분리 및 정제도가 향상되었다. 또한 본 발명의 실시예들에 따르면 기존의 방법보다 우수한 멸균여과와 자동적정기를 이용하여, 고도로 정제된 고순도의 트리소듐 클로린 e6와 PVP 복합체를 제조하였다. 특히 멸균여과를 통한 새로운 위생적인 공정으로 생리활성을 대폭 향상시키고, 초음파를 이용하여 수율을 획기적으로 단시간 향상시킴으로써 대량신약생산에 적합한 공정으로 트리소듐 클로린 e6 복합체를 합성 제조하는 특징을 가진다.In addition, according to embodiments of the present invention, it is possible to obtain a high-purity chlorophyll by a simple and efficient method of removing a substance other than chlorophyll using a solubility difference and polarity of the solvent from the raw material, and an ultrasonic process. In addition, through this, in the synthesis of pheophytin and chlorine e6, an economical process for shortening the reaction time and the amount of the organic solvent was used, and separation and purification were improved. In addition, according to the embodiments of the present invention by using a sterile filtration and automatic titrator superior to the conventional method, highly purified trisodium chlorine e6 and PVP complexes were prepared. In particular, the new hygienic process through sterile filtration greatly improves the physiological activity, and by using ultrasonic waves to significantly improve the yield for a short time has the characteristics of synthesizing trisodium chlorine e6 complex in a process suitable for mass drug production.
이하에서는 본 발명의 실시예들에 따라서 실험한 예들을 설명한다. Hereinafter, examples of experiments according to embodiments of the present invention will be described.
실험 1. 클로로필 추출물의 수득
스피루리나 75kg에 추출용매(에탄올 750리터)를 넣고 초음파 처리(30kHz, 300W)하며 1시간 동안 교반하고 다공성 알루미나 세라믹 필터 (5-20 μm)를 이용, 여과하여 클로로필 추출물을 얻었다. 상기에서 수득한 클로로필 추출물은 하기 조건에서 HPLC(High Pressure Liquid Chromatography) 분석하였다. 이때 사용된 용매는 메탄올, 아세토나이트릴, 디클로로메탄, 물 등이었으며 HPLC 분석은 450 nm에서 수행되었다. 상기에서 수득한 클로로필 추출물에 대한 HPLC 분석 결과는 도 1에 나타내었다. 도 1에 나타낸 HPLC 분석결과에 의하면, 머무름 시간(retention time) 5 내지 8 분에서 클로로필에 해당하는 피크를 관찰할 수 있었으며, 0 내지 3분 사이에서 불순물들이 상당량 존재하는 것으로 확인되었다. 이때 레퍼런스(reference)로는, Sigma-aldrich 회사의 클로로필을 사용하였다.Extraction solvent (750 liters of ethanol) was added to 75 kg of spirulina, sonicated (30 kHz, 300 W), stirred for 1 hour, and filtered using a porous alumina ceramic filter (5-20 μm) to obtain a chlorophyll extract. The chlorophyll extract obtained above was analyzed by HPLC (High Pressure Liquid Chromatography) under the following conditions. The solvent used was methanol, acetonitrile, dichloromethane, water and the like, and HPLC analysis was performed at 450 nm. HPLC analysis of the chlorophyll extract obtained above is shown in FIG. According to the HPLC analysis results shown in FIG. 1, a peak corresponding to chlorophyll was observed at a retention time of 5 to 8 minutes, and it was confirmed that a considerable amount of impurities existed between 0 and 3 minutes. At this time, chlorophyll from Sigma-aldrich company was used as a reference.
실험 2. 고순도 클로로필의 수득
실험 2에서 얻은 클로로필 추출액의 부피가 최대 10%가 되도록 농축하고, 농축된 클로로필 추출물에 같은 부피의 헥산을 넣고 30분동안 초음파 처리(20kHz, 300W)와 함께 교반하였다. 추가로 상기 헥산과 같은 부피의 물을 첨가하고 초음파 처리와 함께 10분 동안 계속 교반하였다. 교반시킨 반응용액을 -10℃ 조건에서 5시간동안 정체시킨 후, 반응용액을 층 분리하여 유기층을 수득하였다. 이후, 유기층을 감압 증류하여 고순도 클로로필을 수득하였다. 수득한 클로로필 추출물에 대한 HPLC 분석 결과는 도 2에 나타내었다. 도 2에 나타낸 HPLC 분석결과에 의하면, 0∼3분 사이의 불순물은 거의 제거되었음을 확인할 수 있었다. 또한 클로로필의 정제도는 약 90%임을 확인할 수 있었다. 이것의 수득율은 해당 출발물질이 함유하는 클로로필의 양에 대비하여 90% 이상 추출되었음을 의미한다.The chlorophyll extract obtained in
실험 3. 클로로필부터 고순도 페오피틴의 수득Experiment 3. Obtaining High Purity Pheophytin from Chlorophyll
실험 2에서 얻어진 클로로필 헥산 용액에 염산 또는 황산을 투여하여 용액의 pH가 2가 되도록 하고 초음파 처리(20kHz, 300W)하면서 1시간 교반 하였다. 반응이 완료된 후, 상기 용액에 상기 클로로필 헥산 용액과 같은 부피의 70% 에탄올을 첨가하고 10분 동안 교반한 후, -10℃에서 3시간동안 정체하여 침전시켰다. 침전물을 동결 건조하여 페오피틴(HPLC 순도 90%, 수율 95%)을 수득하였다(다른 방법으로, 다공성 알루미나 세라믹필터 (5-20 μm)로 여과시켜 건조시키는 방법도 가능하다)Hydrochloric acid or sulfuric acid was administered to the chlorophyll hexane solution obtained in
도 3에 나타낸 HPLC 분석결과에 의하면 페오피틴의 해당 피크를 확인할 수 있었으며, 다른 시간대에서 불순물은 거의 확인되지 않았다. 이상의 산처리 방법을 수행하여 얻은 페오피틴 침전물은 95% 이상의 순도를 가지며, 사용된 클로로필 중량에 대비하여 95% 이상의 수율로 수득된다.According to the HPLC analysis results shown in FIG. 3, the corresponding peak of pheophytin was confirmed, and impurities were hardly identified at other time points. The pheophytin precipitate obtained by the above acid treatment method has a purity of 95% or more and is obtained in a yield of 95% or more based on the weight of chlorophyll used.
실험 4. 페오피틴으로부터 클로린 e6의 합성
실험 3에서 얻어진 페오피틴 1g을 아세톤 50 mL에 용해한 후, 1M 수산화나트륨 수용액을 2.297mL를 첨가하면, 용액의 pH는 약 12가 된다. 이러한 용액을 60℃ 온도로 가열하면서 1시간 동안 교반하였다. 반응이 종결되면, 0.22 μm 마이크로필터를 이용하여 멸균 및 여과하여 클로린 e6 0.653g (HPLC 순도 90%, 수율 90% 이상)을 수득하였다.After dissolving 1 g of pheophytin obtained in Experiment 3 in 50 mL of acetone, when 2.297 mL of 1 M aqueous sodium hydroxide solution was added, the pH of the solution was about 12. This solution was stirred for 1 h while heating to 60 ° C. Upon completion of the reaction, sterilization and filtration using a 0.22 μm microfilter yielded 0.653 g of chlorine e6 (90% HPLC purity, 90% yield).
또한, 수득한 상기 클로린 e6를 고순도로 정제하기 위하여, 클로린 e6 1 g에 대하여 에탄올 100mL에 넣고 1시간 동안 교반하고 멸균 및 여과하여 고순도의 클로린 e6 0.95g (HPLC 순도 95%, 수율 95% 이상)을 수득하였다. 분리 정제한 고순도 클로린 e6의 핵자기공명(NMR) 분석 결과를 확인하였다(도 4). In addition, in order to purify the chlorine e6 obtained in high purity, 1 g of chlorine e6 was added to 100 mL of ethanol, stirred for 1 hour, sterilized and filtered to obtain 0.95 g of high purity chlorine e6 (HPLC purity 95%, yield 95% or more). Obtained. Nuclear magnetic resonance (NMR) analysis of the purified high-purity chlorine e6 was confirmed (Fig. 4).
또한, 수득한 상기 클로린 e6에 대해서는 아세토나이트릴과 0.1% 트리플루오르아세트산 용매를 이용하여 407 nm에서 HPLC 분석하였다(도 5). HPLC 분석결과에 의하면, 머무름 시간(retention time) 3 내지 4분에서 클로린 e6에 해당하는 피크를 관찰할 수 있었으며, 다른 시간대에서 불순물은 거의 확인되지 않았다. 또한 클로린 e6의 정제도는 약 95% 이상임을 확인할 수 있었다. 또한 액체 크로마토그래피 질량분석법 (Liquid Chromatography Mass Spectrometry LC/MS)) 분석결과에 의하면, 클로린 e6의 해당피크를 확인할 수 있었으며, 불순물은 거의 제거되었음을 확인할 수 있었다(도 6).In addition, the obtained chlorine e6 was analyzed by HPLC at 407 nm using acetonitrile and 0.1% trifluoroacetic acid solvent (Fig. 5). As a result of HPLC analysis, peaks corresponding to chlorine e6 were observed at retention time of 3 to 4 minutes, and impurities were hardly identified at other time points. In addition, the purity of chlorine e6 was confirmed to be about 95% or more. In addition, the results of liquid chromatography mass spectrometry (Liquid Chromatography Mass Spectrometry LC / MS) confirmed that the corresponding peak of chlorine e6, it was confirmed that the impurities are almost removed (Fig. 6).
실험 5. 트리소듐 클로린 e6 제조 및 정제
실험 4에서 얻어진 클로린 e6 1g을 물에 용해 시킨 후, 전위차 자동적정기를 이용하여 pH를 7.1까지 맞추고, 물에 용해되지 않는 미세입자를 0.22 μm 마이크로필터를 이용하여 멸균 및 여과하면서 제거한다. 멸균 및 여과 처리된 용액에 다시 산 처리를 하여 전위차 자동적정기를 이용, pH를 2까지 맞춘다. After dissolving 1 g of chlorine e6 obtained in
이후, 클로린 e6 용액으로부터, 고순도 클로린 e6를 수득하거나 또는 고순도 트리소듐 클로린 e6를 수득한다.From the chlorine e6 solution, either high purity chlorine e6 is obtained or high purity trisodium chlorine e6 is obtained.
먼저, 고순도 클로린 e6를 수득하는 과정을 설명한다. First, the process of obtaining high purity chlorine e6 is demonstrated.
클로린 e6 용액을 0.22 μm 마이크로필터를 이용하여 멸균 및 여과하여 클로린 e6를 수득한다. 수득된 클로린 e6를 95% 이상의 아세톤으로 용해한 후 pH를 7.1에 맞추며 멸균 및 여과하고 진공 건조하여 고순도 클로린 e6를 수득한다. The chlorine e6 solution is sterilized and filtered using a 0.22 μm microfilter to obtain chlorine e6. The obtained chlorine e6 was dissolved in 95% or more of acetone, then the pH was adjusted to 7.1, sterilized, filtered and vacuum dried to obtain high purity chlorine e6.
이제, 고순도 트리소듐 클로린 e6를 수득하는 과정을 설명한다.Now, a process for obtaining high purity trisodium chlorine e6 will be described.
클로린 e6 용액을 pH 7 내지 9에 맞추며 트리소듐 클로린 e6를 형성한 후, 0.22 μm 마이크로 필터를 이용하여 멸균 및 여과하고 동결건조하여 고순도 트리소듐 클로린 e6를 수득한다. 수득한 고순도 트리소듐 클로린 e6의 HPLC 분석결과에 의하면, 머무름 시간(retention time) 4 분에서 클로린 e6의 해당 피크를 확인할 수 있었으며, 상용화된 클로린e6 시약 (Frontiers)과 비교하여 95% 이상의 순도를 지니며 불순물은 거의 제거되었음을 확인할 수 있었다(도 7).The chlorine e6 solution is adjusted to pH 7-9 to form trisodium chlorine e6, then sterilized, filtered and lyophilized using a 0.22 μm micro filter to obtain high purity trisodium chlorine e6. HPLC analysis of the obtained high-purity trisodium chlorine e6 confirmed the corresponding peak of chlorine e6 at retention time of 4 minutes, and has a purity of at least 95% compared to commercially available chlorine e6 reagent (Frontiers). It was confirmed that the impurities were almost removed (Fig. 7).
실험 6. 트리소듐 클로린 e6 와 PVP 복합체 제조
실험 5에서 얻어진 트리소듐 클로린 e6 1g을 물에 용해시킨 후, 분자량 10,000 이하 PVP 1g을 첨가하여 1시간 교반 하면서 전위차 자동적정기를 이용하여 pH를 7 내지 9에 맞춘다. 복합체가 형성된 뒤 용액을 0.22 μm 마이크로 필터를 이용하여 멸균 및 여과한다. 멸균 및 여과된 용액을 무균상태에서 동결 건조시켜 복합체를 획득한다. 멸균 및 여과를 통해 미생물의 증가 가능성을 방지하고 엔토톡신의 증가 가능성을 배제한다. After dissolving 1 g of trisodium chlorine e6 obtained in
복합체는 0.22 μm 마이크로필터로 멸균 여과된다. 이후, 멸균 여과된 복합체는 동결건조를 위하여, -20℃ 내지 -40℃의 저온과 20 mbar의 저압을 유지하면서 냉각시키고 콜드트랩 (-70℃ 내지 -80℃)을 이용하여 수분을 제거한다. 상술한 저온 및 저압에서는 수분이 증기상태로 승화되어 제거될 수 있는 진공상태가 된다. 동결상태에서 승화 건조되므로 복합체의 표면이 경화되거나 수축되지 않는다. 한편, 과도한 건조에 의해 피해 입을 수 있으므로 최종 수분의 양이 1.5% - 2%사이에서 건조되도록 유지한다.The complex is sterile filtered with a 0.22 μm microfilter. The sterile filtered complex is then cooled for freeze-drying while maintaining a low temperature of -20 ° C to -40 ° C and a low pressure of 20 mbar and water is removed using a cold trap (-70 ° C to -80 ° C). At the low temperature and low pressure described above, the water becomes a vacuum state in which water can be sublimated and removed. Sublimation drying in the frozen state does not cure or shrink the surface of the composite. On the other hand, since it may be damaged by excessive drying, the amount of final moisture is maintained to be dried between 1.5%-2%.
실험 7. 트리소듐 클로린 e6 와 PVP 복합체 확인 시험Experiment 7. Trisodium Chlorine e6 and PVP Complex Identification Test
본 발명의 일 실시예에 따른 복합체는 물에 잘 용해되며, 함량시험을 위해 조제한 용액은 흑녹색이다. 본 발명의 일 실시예에 따른 복합체 200 mg을 물 25 mL로 희석시키고 10 분간 방치한다. 이 용액 0.2mL을 취하여 100mL 용량 플라스크에 넣고 희석액(95% 에탄올)을 넣어 완전 용해시킨다. 자외가시부 흡광도 측정법에 따라 400 ~ 700nm에서 흡수스펙트럼을 측정할 때 402.4, 503.2, 531.7, 608.0, 및 662.7의 파장들에서 흡수를 나타낸다(도 8 참조). The composite according to an embodiment of the present invention is well dissolved in water, and the solution prepared for the content test is black green. 200 mg of the complex according to one embodiment of the present invention is diluted with 25 mL of water and left for 10 minutes. Take 0.2 mL of this solution into a 100 mL volumetric flask and add a diluent (95% ethanol) to dissolve completely. Absorption is shown at wavelengths of 402.4, 503.2, 531.7, 608.0, and 662.7 when the absorption spectrum is measured at 400-700 nm according to the ultraviolet visible absorbance measurement method (see FIG. 8).
실험 8. 트리소듐 클로린 e6 와 PVP 복합체 함량 시험
본 발명의 일 실시예에 따른 복합체 200 mg을 물 25mL로 희석시킨 용액을 10 분간 방치한다. 10분간 방치후에 상기 용액 0.2mL을 취하여 100mL 용량 플라스크에 넣고 희석액(95% 에탄올)을 넣어 표선까지 채운 다음 녹여 검액으로 한다(표준액: 95% 에탄올). 검액 및 표준액을 가지고 1cm 분광광도계용 셀에 넣어 자외가시부 흡광도 측정법에 따라 662nm에서 투과율을 측정하여 계산한다 (도 9의 수식 참조). 모든 시험물질의 조제는 차광 아래에서 수행한다. 정확성은 각 농도에서 회수율로 계산되고 평균 회수율은 각 농도에서 100% 이내이어야 한다. 정밀성은 각 농도의 회수율에 대한 변동계수로 계산되고 5 % 이하이어야 한다. A solution of 200 mg of the complex according to one embodiment of the present invention diluted with 25 mL of water is left for 10 minutes. After leaving for 10 minutes, take 0.2 mL of the solution, place it in a 100 mL flask, add diluent (95% ethanol) to the mark, and dissolve to prepare a sample solution (standard solution: 95% ethanol). The sample solution and the standard solution were put into a 1 cm spectrophotometer cell and calculated by measuring the transmittance at 662 nm according to the UV-visible absorbance measurement method (refer to the formula of FIG. 9). Preparation of all test substances is carried out under shading. Accuracy is calculated as recovery at each concentration and average recovery should be within 100% of each concentration. Precision should be calculated as a coefficient of variation for the recovery of each concentration and should be less than 5%.
회수율을 계산하는 수식은 다음과 같다.The formula for calculating the recovery rate is as follows.
회수율 (또는 함량) = 역환산된 농도 / 이론농도 ×100Recovery (or content) = inverted concentration / theoretical concentration × 100
실험 8. 트리소듐 클로린 e6 와 PVP 복합체에서 NaCl 정량 시험
본 발명의 일 실시예에 따른 복합체 샘플 약 30mg을 측정한 후 비커에 옮겨 물 50 ml을 넣은 후 녹인다. 물 50ml에 지시약 10% 크롬산칼륨을 넣은 후 0.1N 질산은으로 용액에서 적갈색이 나타나 15초간 유지되는 시점을 최종 적정한 것으로 한다. 위와 같은 방법을 통하여 NaCl의 정량 적정 자료를 바탕으로 복합체의 NaCl 함량을 계산할 수 있으며, 복합체에 NaCl이 함유되어 있는 것을 확인할 수 있다.After measuring about 30 mg of the composite sample according to an embodiment of the present invention, it is transferred to a beaker, 50 ml of water is dissolved. After adding
실험 9. 트리소듐 클로린 e6 와 PVP 복합체에서 클로린e6 분석법Experiment 9.Chlorin e6 assay in trisodium chlorine e6 and PVP complex
UV/VIS Spectrophotometry를 이용하여 생리식염수 중 Chlorin e6에 대하여 분석을 하였고, 이러한 분석을 통해서 정확성 (복합체1), 정밀성(복합체2), 안정성(복합체3)을 조사하였다.The chlorine e6 in physiological saline was analyzed using UV / VIS Spectrophotometry. Through this analysis, the accuracy (complex 1), precision (complex 2) and stability (composite 3) were investigated.
100 mg/mL (Chlorin e6 로서)의 주사용 조제물을 조제하기 위해 복합체에 부형제를 넣은 후 약 30 분간 초음파 진탕하여 녹인다. 저농도의 조제물은 고농도 조제물(100 mg/mL)에서 목적 농도 1 mg/mL이 되도록 부형제를 이용하여 희석하여 준비한다. 모든 시험물질의 조제는 차광 아래에서 수행한다. 부형제 중 2.5, 5, 10 mg/mL의 Chlorin e6는 일내(intra-day) 및 일간(inter-day) 분석을 통해 평가한다. 일내 분석은 한 농도당 세 개의 시료를 각각 조제하여 세 농도에서 평가한다. 일간 분석은 일내 분석과 동일한 방법으로 최소 3일의 결과로 평가하고, 실험자간 재현성을 확인하기 위하여 그 중 한 샘플은 다른 실험자가 수행한다. 정확성은 각 농도에서 회수율로 계산되고 평균 회수율은 각 농도에서 100% 이내이어야 한다. 정밀성은 각 농도의 회수율에 대한 변동계수로 계산되고 5% 이하이어야 한다. 복합체의 안정성은 부형제 중 2.5, 10 mg/mL의 복합체 시료를 각 보관 조건에 보관 후에 중층에서 세 번 취한다. 각 샘플은 차광하여 냉장에서 약 7일 간 보관한다. 적합기준은 이론농도 대비 함량은 100% 이내이어야 한다. 도 10을 참조하면, 정확성, 정밀성, 안정성 클로린 e6에 대한 분석결과를 참고할 수 있다.To prepare an injection preparation of 100 mg / mL (as Chlorin e6), add excipients to the complex and dissolve by ultrasonic shaking for about 30 minutes. Low concentration preparations are prepared by dilution with excipients from high concentration preparations (100 mg / mL) to the desired concentration of 1 mg / mL. Preparation of all test substances is carried out under shading. Chlorin e6 at 2.5, 5 and 10 mg / mL in excipients are assessed by intra-day and inter-day analysis. In-day analysis is performed at three concentrations by preparing three samples per concentration. The daily analysis is evaluated with a result of at least 3 days in the same manner as the daily analysis, and one sample is performed by another experimenter to confirm the reproducibility between the experimenters. Accuracy is calculated as recovery at each concentration and average recovery should be within 100% of each concentration. Precision is calculated as the coefficient of variation for the recovery of each concentration and should be less than 5%. The stability of the complex is taken three times in the middle layer after storage of 2.5, 10 mg / mL of the complex sample in excipients at each storage condition. Each sample is shaded and stored for about 7 days in refrigeration. The conformance criteria should be within 100% of the theoretical concentration. Referring to FIG. 10, reference may be made to an analysis result of chlorine e6 for accuracy, precision, and stability.
상기와 같이 본 발명은 비록 한정된 실시예와 도면에 의해 설명되었으나, 본 발명은 상기의 실시예에 한정되는 것은 아니며, 본 발명이 속하는 분야에서 통상의 지식을 가진 자라면 이러한 기재로부터 다양한 수정 및 변형이 가능하다.As described above, the present invention has been described by way of limited embodiments and drawings, but the present invention is not limited to the above embodiments, and those skilled in the art to which the present invention pertains various modifications and variations from such descriptions. This is possible.
그러므로, 본 발명은 설명된 실시예에 국한되어 정해져서는 아니 되며, 후술하는 특허청구범위뿐 아니라 이 특허청구범위와 균등한 것들에 의해 정해져야 한다.Therefore, the present invention should not be limited to the described embodiments, but should be defined not only by the claims below but also by equivalents thereof.
Claims (16)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0170548 | 2016-12-14 | ||
| KR1020160170548A KR20180068649A (en) | 2016-12-14 | 2016-12-14 | Process for preparing high purity trisodium Chlorin e6 and PVP complex, and Chlorin e6 from spirulina extracts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018110777A1 true WO2018110777A1 (en) | 2018-06-21 |
Family
ID=62559741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2017/005282 Ceased WO2018110777A1 (en) | 2016-12-14 | 2017-05-22 | Method for producing composite of high purity trisodium chlorin e6 and polyvinylpyrrolidone, and method for producing chlorin e6 |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20180068649A (en) |
| WO (1) | WO2018110777A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101965979B1 (en) * | 2017-11-02 | 2019-04-04 | 서원대학교산학협력단 | Method for Extracting chlorophylls from Spirulina |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120021798A (en) * | 2010-08-17 | 2012-03-09 | 주식회사 루맥스바이오 | Methods for preparing high purity chlorophyll and chlorin e6 from chlorophyll extracts |
| KR101138438B1 (en) * | 2011-08-05 | 2012-04-26 | 다이아텍코리아 주식회사 | Methods for Preparing Powder Chlorophyll a and Photosensitizer from Spirulina |
-
2016
- 2016-12-14 KR KR1020160170548A patent/KR20180068649A/en not_active Ceased
-
2017
- 2017-05-22 WO PCT/KR2017/005282 patent/WO2018110777A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120021798A (en) * | 2010-08-17 | 2012-03-09 | 주식회사 루맥스바이오 | Methods for preparing high purity chlorophyll and chlorin e6 from chlorophyll extracts |
| KR101138438B1 (en) * | 2011-08-05 | 2012-04-26 | 다이아텍코리아 주식회사 | Methods for Preparing Powder Chlorophyll a and Photosensitizer from Spirulina |
Non-Patent Citations (3)
| Title |
|---|
| ISAKAU, H. A.: "Toward understanding the high PDT efficacy of chlorin e6-polyvinylpyrrolidone formulations: Photophysical and molecular aspects of photosensitizer-polymer interaction in vitro", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 92, no. 3, 24 June 2008 (2008-06-24), pages 165 - 174, XP024528939 * |
| RYU, A-R.: "Chlorin e6-mediated photodynamic inactivation with halogen light against microbes and fungus", TOXICOLOGY AND ENVIRONMENTAL HEALTH SCIENCES, vol. 7, no. 3, 3 November 2015 (2015-11-03), pages 231 - 238, XP035737566 * |
| SIMON, D.: "Extraction and quantification of chlorophyll a from freshwater green algae", WATER RESEARCH, vol. 32, no. 7, July 1998 (1998-07-01), pages 2220 - 2223, XP004133799 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180068649A (en) | 2018-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109265443B (en) | Heterocyclic compounds as ASK inhibitors and uses thereof | |
| DE69930947T2 (en) | PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF INTERACTION BETWEEN MDM2 AND MDM2 | |
| Muhammad et al. | Investigation of Una De Gato I. 7-Deoxyloganic acid and 15N NMR spectroscopic studies on pentacyclic oxindole alkaloids from Uncaria tomentosa | |
| HRP20020334A2 (en) | Process for the preparation of amorphous atorvastatin calcium | |
| CN109790171A (en) | Pyrrolobenzodiazepines dimer precursor and its ligand-connector conjugated compound | |
| US9657017B2 (en) | Crystal form of (R)-praziquantel and preparation method and application thereof | |
| WO2019107896A1 (en) | Fusion protein comprising glutathione-s-transferase and protein having binding affinity target cell or target protein, and use thereof | |
| WO2016167385A1 (en) | Composition-ii for preventing or treating alzheimer's disease, comprising lycopodiella cernua extract or compound isolated therefrom | |
| WO2012173458A9 (en) | Stabilized active materials contained in plant cells and method for preparing same | |
| WO2018110777A1 (en) | Method for producing composite of high purity trisodium chlorin e6 and polyvinylpyrrolidone, and method for producing chlorin e6 | |
| DE69329606T2 (en) | 2,3-bis-carboxaamidomethyl substituted oxiranes as inhibitors of HIV protease and their use for the treatment of AIDS protease | |
| WO2018190493A1 (en) | Method for synthesizing sucralfate and sucralfate thereby | |
| WO2018212531A1 (en) | Pharmaceutical composition for preventing or treating dementia and improving cognitive function, comprising glasswort extract | |
| AU2022233180B2 (en) | Heteroaryl compounds as inhibitors of rip2 kinase, composition and application thereof | |
| CZERWINSKI et al. | New N-alkyl derivatives of amphotericin B synthesis and biological properties | |
| WO2011118929A2 (en) | Novel crystal forms of epirubicin hydrochloride | |
| WO2021029450A1 (en) | Novel pyrimidine sulfonamide derivative, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | |
| CZ276796A3 (en) | Enhanced synthesis method of 6,9-bis£(2-aminoethyl)amino|benzo £g|isoquinoline-5,10-dione and dimaleate salts thereof | |
| KR20190106834A (en) | Process for preparing high purity trisodium Chlorin e6 and PVP complex, and Chlorin e6 from spirulina extracts | |
| Czernecki et al. | One-step conversion of thymidine into 2, 3′-anhydro derivatives | |
| CN110023414B (en) | Method for preparing indigo carmine | |
| KR101127600B1 (en) | A Novel Naringenin Derivative, 7-Trimethyl Aceto-naringenin and A Use as a Anti-cancer Drug thereof | |
| RU2151152C1 (en) | Polymorphes 6-n-(l-ala-l-ala) of trovafloxacine | |
| EP0304157A1 (en) | Antitumor and antiviral alkaloids | |
| JP7393457B2 (en) | Furan aspidospermine dimer or its pharmaceutically acceptable salt, its production method and application, and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17881882 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17881882 Country of ref document: EP Kind code of ref document: A1 |